Integumentary system disorder
MONDO:0002051A disease involving the integumental system.
Also known as: disease of integumental system, disease or disorder of integumental system, disorder of integumental system, integumental system disease, integumental system disease or disorder, integumentary disease, disorder of integument
4568 clinical trials for this condition and its sub-types, 0 tagged with Integumentary system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Integumentary system disorder
-
Skin disorder 138 trials · 3,975 incl. sub-types
72 sub-types
- Dermatitis 65 trials · 1,626 incl. sub-types Sub-types →
- Skin neoplasm 170 trials · 994 incl. sub-types Sub-types →
- Hereditary skin disorder 7 trials · 885 incl. sub-types Sub-types →
- Skin disorder caused by infection 3 trials · 350 incl. sub-types Sub-types →
- Systemic sclerosis 261 trials · 295 incl. sub-types Sub-types →
- Chronic ulcer of skin 48 trials · 270 incl. sub-types Sub-types →
- Vesiculobullous skin disease 3 trials · 216 incl. sub-types Sub-types →
- Sweat gland disorder 7 trials · 150 incl. sub-types Sub-types →
- Skin vascular disease 5 trials · 135 incl. sub-types Sub-types →
- Epidermal disease 0 trials · 131 incl. sub-types Sub-types →
- Dermis disorder 0 trials · 103 incl. sub-types Sub-types →
- Sebaceous gland disorder 0 trials · 101 incl. sub-types Sub-types →
- Severe cutaneous adverse reaction 62 trials · 68 incl. sub-types Sub-types →
- Skin pigmentation disorder 12 trials · 63 incl. sub-types Sub-types →
- Lipodystrophy 30 trials · 48 incl. sub-types Sub-types →
- Lichen disease 0 trials · 47 incl. sub-types Sub-types →
- Hereditary epidermal appendage anomaly 0 trials · 45 incl. sub-types Sub-types →
- Rosacea 32 trials Sub-types →
- Keratosis 5 trials · 30 incl. sub-types Sub-types →
- Exanthem 11 trials · 28 incl. sub-types Sub-types →
- Reactive cutaneous fibrous lesion 0 trials · 28 incl. sub-types Sub-types →
- Prurigo nodularis 26 trials
- Toxic dermatosis 0 trials · 20 incl. sub-types Sub-types →
- Pyoderma 2 trials · 16 incl. sub-types Sub-types →
- Hand-foot syndrome 9 trials
- Cutaneous mucinosis 2 trials · 5 incl. sub-types Sub-types →
- Oral erosive lichen 5 trials
- Sunburn 5 trials
- Skin sarcoidosis 3 trials
- Actinic prurigo 2 trials
- Cutaneous sclerosis 2 trials
- Erythema multiforme 2 trials
- Keratosis pilaris 2 trials Sub-types →
- Paronychia 2 trials Sub-types →
- Skin atrophy 2 trials
- Wells syndrome 1 trial
- Aquagenic pruritus 1 trial
- Chronic actinic dermatitis 1 trial
- Erythematosquamous dermatosis 1 trial
- Hand dermatosis 1 trial
- Livedoid vasculopathy 1 trial
- Solar urticaria 1 trial
- Achenbach syndrome 0 trials
- Bazex-Dupre-Christol syndrome 0 trials Sub-types →
- Boudhina Yedes Khiari syndrome 0 trials
- Jessner lymphocytic infiltration of the skin 0 trials
- Nicolau syndrome 0 trials
- Parana hard-skin syndrome 0 trials
- Acquired kinky hair syndrome 0 trials
- Ainhum 0 trials
- Cheilitis glandularis 0 trials
- Congenital lethal erythroderma 0 trials
- Corticosteroid-sensitive aseptic abscess syndrome 0 trials
- Cutaneous pseudolymphoma 0 trials
- Erosive pustular dermatosis of the scalp 0 trials
- Erythema palmare hereditarium 0 trials
- Facial dermatosis 0 trials Sub-types →
- Granuloma faciale 0 trials
- Hematohidrosis 0 trials
- Hyperglobulinemic purpura 0 trials
- Interstitial granulomatous dermatitis with arthritis 0 trials
- Leg dermatosis 0 trials
- Mongolian spot 0 trials
- Multiple benign circumferential skin creases on limbs 0 trials Sub-types →
- Nephrogenic systemic fibrosis 0 trials
- Non-neoplastic nevus 0 trials
- Pellagra 0 trials
- Pityriasis rotunda 0 trials
- Primary cutaneous plasmacytosis 0 trials
- Pseudoxanthoma elasticum-like papillary dermal elastolysis 0 trials
- Scalp dermatosis 0 trials
- Sclerema neonatorum 0 trials
-
Integumentary system cancer 0 trials · 1,088 incl. sub-types
7 sub-types
- Skin cancer 118 trials · 801 incl. sub-types Sub-types →
- Breast adenocarcinoma 36 trials · 279 incl. sub-types Sub-types →
- Atypical lobular breast hyperplasia 11 trials
- Dermatofibrosarcoma protuberans 11 trials Sub-types →
- Bartholin gland carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Breast diffuse large B-cell lymphoma 1 trial
- Nipple carcinoma 0 trials Sub-types →
-
Disorder of pilosebaceous unit 7 trials · 341 incl. sub-types
9 sub-types
- Hair anomaly 0 trials · 228 incl. sub-types Sub-types →
- Sebaceous gland disorder 0 trials · 101 incl. sub-types Sub-types →
- Folliculitis 1 trial · 8 incl. sub-types Sub-types →
- Hypotrichosis 5 trials · 6 incl. sub-types Sub-types →
- Piedra 0 trials · 2 incl. sub-types Sub-types →
- Katsantoni-Papadakou-Lagoyanni syndrome 0 trials
- Hair follicle neoplasm 0 trials Sub-types →
- Hypertrichosis 0 trials Sub-types →
- Trichostasis spinulosa 0 trials
-
Skin appendage disorder 0 trials · 244 incl. sub-types
4 sub-types
- Hair anomaly 0 trials · 228 incl. sub-types Sub-types →
- Epidermal appendage tumor 3 trials · 8 incl. sub-types Sub-types →
- Internal hordeolum 1 trial · 6 incl. sub-types Sub-types →
- Piedra 0 trials · 2 incl. sub-types Sub-types →
-
Integumentary system benign neoplasm 0 trials · 121 incl. sub-types
8 sub-types
- Benign neoplasm of skin 3 trials · 118 incl. sub-types Sub-types →
- Adiposis dolorosa 2 trials
- Intraductal breast papilloma 1 trial Sub-types →
- Bartholin gland benign neoplasm 0 trials Sub-types →
- Adenoma of nipple 0 trials
- Familial multiple lipomatosis 0 trials
- Hemangioma of subcutaneous tissue 0 trials
- Multiple symmetric lipomatosis 0 trials Sub-types →
-
Cutaneous mycosis 1 trial · 118 incl. sub-types
5 sub-types
- Tinea infection 1 trial · 116 incl. sub-types Sub-types →
- Superficial mycosis 0 trials · 88 incl. sub-types Sub-types →
- Dermatomycosis 1 trial Sub-types →
- Cutaneous basidiobolomycosis 0 trials
- Subcutaneous mycosis 0 trials Sub-types →
-
Subcutaneous tissue disorder 0 trials · 64 incl. sub-types
19 sub-types
- Lipedema 41 trials
- Fibrodysplasia ossificans progressiva 10 trials
- Cerebrotendinous xanthomatosis 6 trials
- CLOVES syndrome 5 trials
- Adiposis dolorosa 2 trials
- Mycetoma 1 trial
- Nodular non-suppurative panniculitis 1 trial
- FLOTCH syndrome 0 trials
- Pierpont syndrome 0 trials
- Roch-Leri mesosomatous lipomatosis 0 trials
- Cytophagic histiocytic panniculitis 0 trials
- Dissecting cellulitis of the scalp 0 trials
- Encephalocraniocutaneous lipomatosis 0 trials
- Familial angiolipomatosis 0 trials
- Familial multiple lipomatosis 0 trials
- Hemangioma of subcutaneous tissue 0 trials
- Isolated anhidrosis with normal sweat glands 0 trials
- Multiple symmetric lipomatosis 0 trials Sub-types →
- Nodular fasciitis 0 trials Sub-types →
-
Cutis laxa 37 trials · 39 incl. sub-types
2 sub-types
- Inherited cutis laxa 0 trials · 2 incl. sub-types Sub-types →
- Acquired cutis laxa 0 trials
-
X-linked ichthyosis syndrome 0 trials · 37 incl. sub-types
2 sub-types
- CHILD syndrome 37 trials
- Syndromic recessive X-linked ichthyosis 0 trials
-
Keratinization disease 1 trial · 31 incl. sub-types
2 sub-types
- Keratosis 5 trials · 30 incl. sub-types Sub-types →
- Epidermolytic ichthyosis 1 trial Sub-types →
-
Nail disorder 2 trials · 18 incl. sub-types
7 sub-types
- Nail infection 0 trials · 14 incl. sub-types Sub-types →
- Paronychia 2 trials Sub-types →
- Basaran Yilmaz syndrome 0 trials
- Judge Misch wright syndrome 0 trials
- Inherited isolated nail anomaly 0 trials Sub-types →
- Nail anomaly 0 trials
- Nail tumor 0 trials Sub-types →
-
Pseudoxanthoma elasticum (inherited or acquired) 5 trials · 7 incl. sub-types
2 sub-types
- Inherited pseudoxanthoma elasticum 0 trials · 7 incl. sub-types Sub-types →
- Acquired pseudoxanthoma elasticum 0 trials
-
Demodicidosis 5 trials · 6 incl. sub-types
2 sub-types
- Demodex folliculitis 5 trials
- Demodicidosis of sebaceous gland 0 trials
-
Panniculitis 3 trials · 6 incl. sub-types
6 sub-types
- Lipodermatosclerosis 1 trial
- Nodular non-suppurative panniculitis 1 trial
- Panniculitis and localized lipodystrophy 1 trial
- Cytophagic histiocytic panniculitis 0 trials
- Erythema nodosum 0 trials
- Lupus erythematosus panniculitis 0 trials
-
Mucosulfatidosis 4 trials
-
Sjogren-Larsson syndrome 3 trials
-
1 sub-type
- Melanoma-pancreatic cancer syndrome 0 trials
-
Breast fibrosis 2 trials
-
Rombo syndrome 1 trial
-
Familial tumoral calcinosis 1 trial
5 sub-types
- Familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome 0 trials
- Normophosphatemic familial tumoral calcinosis 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 1 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 2 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 3 0 trials
-
Ichthyosis prematurity syndrome 1 trial
-
Bartholin gland neoplasm 0 trials · 1 incl. sub-types
2 sub-types
- Bartholin gland carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Bartholin gland benign neoplasm 0 trials Sub-types →
-
ANE syndrome 0 trials
-
Bartholin duct cyst 0 trials
-
Neu-Laxova syndrome 0 trials
3 sub-types
- Neu-Laxova syndrome 1 0 trials
- Neu-Laxova syndrome 2 0 trials
- Neu-laxova syndrome due to 3-phosphoserine phosphatase deficiency 0 trials
-
Proteus-like syndrome 0 trials
-
Benign mammary dysplasia 0 trials
-
Keratoderma hereditarium mutilans 0 trials
-
Nipple neoplasm 0 trials
3 sub-types
- Adenoma of nipple 0 trials
- Infiltrating nipple syringomatous adenoma 0 trials
- Nipple carcinoma 0 trials Sub-types →
-
Paraneoplastic cutaneous syndrome 0 trials
1 sub-type
- Paraneoplastic pemphigus 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1575 trials in this tab.
-
Engineered immune cells target CD5 in Hard-to-Treat T-Cell lymphomas
Cure Recruiting nowResearchers are testing a new immune cell therapy called CD5 CAR-T in people with mature T-cell lymphomas that have come back or stopped responding to standard treatment. The trial enrolls about 36 participants, ages 14 to 70, who have few remaining options. Participants receive …
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Gene therapy offers hope for babies with 'Bubble Boy' disease
Cure Recruiting nowThis study tests a new gene therapy for children with a severe immune disorder called Artemis-SCID, where the body cannot fight infections. Doctors take the child's own blood stem cells, fix the faulty gene in a lab, and put the corrected cells back. The goal is to rebuild a work…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Cure
Last updated Jun 27, 2026 12:00 UTC
-
Could a new vaccine beat chickenpox? large trial underway
Vaccine Recruiting nowThis study tests a new chickenpox vaccine called NBP608 in about 780 children aged 1 to 12 years. The vaccine is compared to licensed vaccines to see how well it triggers immunity and if it is safe. Children receive one or two shots, and researchers monitor their immune response …
Phase 3 • Sponsor: SK Bioscience Co., Ltd. • Aim: Vaccine
Last updated Sep 17, 2026 00:00 UTC
-
MRNA shot takes aim at the nerve pain of shingles
Vaccine Recruiting nowResearchers are testing an experimental mRNA vaccine called ABO1108 to see whether it can prevent herpes zoster, the painful rash also known as shingles. The trial enrolls adults aged 40 and older, including people whose long-term conditions are stable. Participants receive two i…
Phase 3 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Sep 16, 2026 00:00 UTC
-
Can the shingles vaccine protect transplant patients? new study aims to find out
Vaccine Recruiting nowThis study tests the shingles vaccine (SHINGRIX) in 160 people: transplant recipients on different immunosuppressant drugs and their healthy housemates. Researchers will measure immune responses at five time points over a year to see if the vaccine works well in these groups. The…
Sponsor: Central Adelaide Local Health Network Incorporated • Aim: Vaccine
Last updated Jun 27, 2026 12:05 UTC
-
Can an oral drug match a standard injection for Hard-to-Treat intestinal Behçet's?
Disease control Recruiting nowResearchers compare two drugs, baricitinib and adalimumab, in people with intestinal Behçet's syndrome that has not improved with standard treatments. Participants receive one of the drugs for six months while continuing their existing steroids or immune-modulating medicines. The…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
New STING agonist drug enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
New pill could shrink abnormal vessels in rare childhood disorders
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called KP-001 in 150 people aged 2 and older with venous malformations, lymphatic malformations, or KTS/CLOVES syndrome. Participants receive either KP-001 or a placebo for 24 weeks, then everyone gets the drug for another 28 weeks. The goal …
Phase 3 • Sponsor: Kaken Pharmaceutical • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Could a common arthritis drug tame rare immune disease symptoms?
Disease control Recruiting nowThis early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
New shot could ease skin tightening in rare disease
Disease control Recruiting nowThis study tests an experimental drug called efgartigimod PH20 SC in adults with systemic sclerosis, a disease that causes skin thickening and organ problems. About 81 participants will receive either the drug or a placebo as a shot under the skin for up to 48 weeks. Researchers …
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Gold nanoparticles join fight against advanced melanoma in tiny safety trial
Disease control Recruiting nowThis early-stage trial tests whether injecting gold nanoparticles into tumors, followed by radiation and an immunotherapy drug, is safe for people with advanced melanoma. Only 6 participants will be enrolled. The goal is to check for side effects, not to see if the treatment work…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
New short radiation regimen aims to cut side effects in breast cancer treatment
Disease control Recruiting nowThis study is testing whether a shorter, higher-dose radiation treatment (APBI) given over just three days is safe and effective for women with early-stage breast cancer or DCIS who have had a lumpectomy. The goal is to see if this approach causes fewer or milder side effects com…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Viruses that kill bacteria: a new weapon against superbugs?
Disease control Recruiting nowThis study tests personalized phage therapy in people with serious infections that have not responded to antibiotics or surgery. Researchers will collect data before, during, and after treatment to see how safe and effective phage therapy is, and how it affects different body sit…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Fish oil capsules could ease rare muscle disease
Disease control Recruiting nowThis study tests whether omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can reduce disease activity in adults with dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. About 300 participants will take either fish oil cap…
Phase 2 • Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
New pill could stop and treat dangerous swelling attacks
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called deucrictibant in adults with acquired angioedema due to C1 inhibitor deficiency, a rare condition causing sudden, painful swelling attacks. The study has three parts: one to see if a daily extended-release tablet can prevent attacks, a…
Phase 3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
Poop pills? stool transplants may ease immunotherapy side effects
Disease control Recruiting nowThis early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a higher dose of this pill regrow hair in severe alopecia?
Disease control Recruiting nowThis study tests two daily doses (50 mg and 100 mg) of the medicine ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss on the scalp and body. The 50 mg dose is already approved, and researchers want to see if …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cell therapy trial aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the therapy might h…
Early phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a daily nail film clear stubborn toenail fungus?
Disease control Recruiting nowResearchers are testing a topical filmogel device called URGO MICKAEL on mild to moderate toenail fungus. About 54 adults with one or two damaged big toenails apply the device daily for up to six months. The study measures whether fungal cultures from the treated nail turn negati…
Sponsor: CEN Biotech • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a common arthritis drug tame a rare, fatal blood vessel disease?
Disease control Recruiting nowThis study tests whether baricitinib, a drug already approved for arthritis, can help people with Kohlmeier-Degos (KD) disease that affects the brain and spine. KD causes inflammation and blood clots that damage small blood vessels, and there is currently no treatment. The trial …
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody AU-007 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…
Phase 1/2 • Sponsor: Aulos Bioscience, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new pill bring back skin color in vitiligo?
Disease control Recruiting nowThis study tests a drug called zasocitinib in adults with nonsegmental vitiligo, an autoimmune condition that causes white patches on the skin. About 200 participants will take either the drug or a placebo for up to a year. The main goal is to see if the drug can improve skin col…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug ease the joint pain of psoriatic arthritis?
Disease control Recruiting nowThis trial tests an experimental drug called DDY391 in about 220 adults with moderate to severe psoriatic arthritis, a condition that causes joint pain, swelling, and skin patches. Researchers want to see whether DDY391 can reduce joint symptoms better than a placebo and at what …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on muscle disease
Disease control Recruiting nowThis study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…
Phase 2/3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Hope for scleroderma: new pill aims to halt disease progression
Disease control Recruiting nowThis Phase 3 trial tests whether the oral drug nerandomilast can slow disease progression in adults with systemic sclerosis (scleroderma). About 448 participants will be randomly assigned to receive either nerandomilast or a placebo twice daily for up to 4 years. Researchers will…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase 1/2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a JAK inhibitor bring back hair in kids with severe alopecia?
Disease control Recruiting nowThis trial tests whether upadacitinib, an oral medication that calms the immune system, can help children with severe alopecia areata—a condition where the immune system attacks hair follicles, causing significant hair loss. Children aged 6 to 17 with at least 50% scalp hair loss…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could a simple pill shield HAE patients from Procedure-Triggered attacks?
Disease control Recruiting nowThis trial tests whether the drug sebetralstat can prevent swelling attacks in people with hereditary angioedema (HAE) when taken before a medical procedure. Participants aged 12 and older with HAE type I or II will take sebetralstat just before their scheduled procedure. The mai…
Phase 4 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for breast cancer recurrence: repeat radiation may spare the breast
Disease control Recruiting nowThis study is for women aged 51 or older whose breast cancer has returned or who have a new cancer in the same breast. The goal is to see if giving a focused, short course of radiation before surgery is safe and effective enough to allow breast-conserving treatment instead of mas…
Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug aims to halt lung damage in autoimmune patients
Disease control Recruiting nowThis study tests whether the drug nerandomilast can slow lung scarring in people with autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults whose lung function hasn't improved with standard treatment will take either nerandomilast or a placebo twice daily…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug BL-M14D1 targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
DNA-Guided immunotherapy trial aims to match drug to tumor
Disease control Recruiting nowThis study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…
Phase 2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could less be more? new study tests lower doses of cancer drug
Disease control Recruiting nowThis study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a shot replace the knife for skin cancer?
Disease control Recruiting nowThis phase 3 trial tests whether injecting the drug cemiplimab directly into early-stage skin cancer tumors can work as well as surgery. About 369 people with small tumors on the head, neck, hand, or shin will be randomly assigned to get either the injections or standard surgery.…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug hopes to ease rare muscle diseases
Disease control Recruiting nowThis Phase 3 trial tests a drug called dazukibart in people with active dermatomyositis or polymyositis, rare diseases that cause muscle weakness and inflammation. About 318 adults will receive either the drug or a placebo by IV every 4 weeks for 48 weeks. The study aims to see i…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug INCA036873 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Half the chemo, same punch? trial tests lower bleomycin dose for skin tumors
Disease control Recruiting nowResearchers test whether halving the bleomycin dose in electrochemotherapy controls skin tumors as well as the standard dose. Electrochemotherapy gives chemotherapy followed by brief electrical pulses that help the drug enter tumor cells. Adults with cutaneous or subcutaneous can…
Phase 4 • Sponsor: Julie Gehl • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug aims to regrow hair in alopecia patients
Disease control Recruiting nowThis early-stage study tests a new drug called HCW9302 in 30 adults with alopecia areata, a condition causing patchy or total hair loss. The drug is an IL-2 fusion protein given by injection. The main goal is to check safety and find the right dose for future studies, not to prov…
Phase 1 • Sponsor: HCW Biologics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for rare blood cancer: experimental drug targets mast cells
Disease control Recruiting nowThis study tests an experimental drug called CGT9486 (bezuclastinib) in people with advanced systemic mastocytosis, a rare and serious blood disorder. The drug aims to control the disease by blocking a key protein that drives abnormal mast cell growth. About 140 adults with aggre…
Phase 2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new drug clear the skin in lichen planus?
Disease control Recruiting nowThis trial is testing an investigational drug called GIA632 in people with moderate-to-severe cutaneous lichen planus, a skin condition that causes itchy, purple bumps. The study aims to see if GIA632 can clear or nearly clear the skin rash and reduce itching compared to a placeb…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug trial hopes to thicken skin Disease's fate
Disease control Recruiting nowThis study tests an experimental drug called MTX-474 in 85 people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and organ damage. Participants will receive either MTX-474 or a placebo for 24 weeks to see if the drug safely reduces skin thickne…
Phase 2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug AZD5492 tested for autoimmune diseases in first human study
Disease control Recruiting nowThis Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cream could ease painful skin condition
Disease control Recruiting nowThis early-stage trial tests a cream called ruxolitinib on people with hidradenitis suppurativa, a condition causing painful lumps under the skin. The study includes 24 adults and teens and focuses on safety and how much of the drug gets into the body. Participants apply the crea…
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a pill tame severe eczema? a new trial puts QX-4533 to the test
Disease control Recruiting nowThis early-stage trial tests an oral drug called QX-4533 in healthy volunteers and in people with moderate-to-severe atopic dermatitis, a common type of eczema. The main goal is to check the drug's safety and how the body processes it, while also looking for early signs that it m…
Phase 1 • Sponsor: QuantX Biosciences, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a gut bacteria boost melanoma treatment? new trial aims to find out
Disease control Recruiting nowThis study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can help stop advanced melanoma from growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or immunotherapy plus L…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a simple injection dissolve painful calcium lumps in rare diseases?
Disease control Recruiting nowThis study tests whether injecting sodium thiosulfate directly into abnormal calcium deposits can shrink them and reduce pain. It includes people with three rare conditions: systemic sclerosis, dermatomyositis, and a genetic disorder called iPPSD2. Participants receive up to 11 i…
Phase 2 • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
A pill that could let people with rare sunlight disorder step outside without pain
Disease control Recruiting nowResearchers are testing an oral drug called PORT-77 in people with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), rare conditions that cause severe pain after sunlight exposure. The trial enrolls about 225 adults and adolescents aged 12 and older. It compa…
Phase 2/3 • Sponsor: Portal Therapeutics, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Promising new combo tackles melanoma brain metastases in phase 2 trial
Disease control Recruiting nowThis phase 2 trial compares two treatment combinations for people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib and binimetinib) plus an immunotherapy (nivolumab), while the other gets two immunotherapies (ipilimumab a…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
HS patients who responded to drug get extended access in new study
Disease control Recruiting nowThis study offers continued treatment with povorcitinib for up to 600 adults with hidradenitis suppurativa who completed a prior trial and saw benefit. The main goal is to track side effects over time, with a secondary focus on reducing skin abscesses, nodules, and tunnels. Parti…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase 1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets rosacea inflammation at its source
Disease control Recruiting nowThis study tests an oral medication called remibrutinib for adults with moderate-to-severe papulopustular rosacea, a skin condition causing red bumps and pustules on the face. The drug works by blocking a protein involved in inflammation. Researchers will measure whether it reduc…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New cream could ease painful skin condition lichen sclerosus
Disease control Recruiting nowThis study tests a cream called delgocitinib for lichen sclerosus, a skin condition that causes itching, pain, and scarring in the genital area. About 652 adults with mild to severe disease will apply the cream twice daily for up to 52 weeks. Researchers will check if the cream i…
Phase 3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Promising cream may help kids with vitiligo regain skin color
Disease control Recruiting nowThis study tests a cream called ruxolitinib in 180 children with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the cream can safely bring back color, especially on the face. Participants will apply the cream daily for several mont…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug aims to calm severe eczema without steroids
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Phase 3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail targets rare blood cancer in promising trial
Disease control Recruiting nowThis study tests a new treatment plan for people with a rare and aggressive blood cancer called BPDCN. The plan combines two targeted drugs (tagraxofusp and venetoclax) with standard chemotherapy to kill cancer cells. The goal is to see if this combination can control the disease…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New surgical trick could save diabetic feet from amputation
Disease control Recruiting nowThis study tests a device that moves a small piece of shinbone to improve blood flow and help heal chronic foot ulcers in people with diabetes. One hundred adults with stubborn ulcers that haven't healed after 12 weeks will be enrolled. The goal is to see if this procedure, added…
Sponsor: Biodynamik, Inc • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill shows promise for controlling painful skin condition in long-term trial
Disease control Recruiting nowThis phase 3 study tests the long-term safety and effectiveness of remibrutinib, an oral drug, in 710 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants have already completed a prior remibrutinib study. …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New cord blood transplant recipe aims to beat tough blood cancers
Disease control Recruiting nowThis study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Narrow beams, big hope: new radiation approach tested for skin tumors
Disease control Recruiting nowThis study tests a new radiation method called minibeam therapy for people with skin or soft tissue tumors that have come back or spread. The treatment uses a special device to split a wide radiation beam into many tiny beams, which may reduce damage to healthy tissue. The goal i…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called galvokimig in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if different doses can reduce skin redness, itching, and rash better than a placebo. Participants will receive injections and be monitored for 16…
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug could help rare fat disorder patients
Disease control Recruiting nowThis study tests a new drug called mibavademab for people with generalized lipodystrophy, a rare condition where the body lacks fat tissue. The goal is to see if the drug can improve blood sugar, lower blood fats, and reduce liver fat. About 28 children and adults will take part …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a daily pill regrow hair in alopecia areata? a trial seeks answers
Disease control Recruiting nowThis phase 3 trial tests whether the experimental drug ritlecitinib can safely and effectively regrow hair in people aged 12 and older with moderate alopecia areata, a condition causing patchy hair loss. Participants take a daily capsule for 24 weeks, with some receiving placebo.…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New RNA drug aims to stop debilitating swelling attacks in rare genetic condition
Disease control Recruiting nowThis phase 3 trial is testing an experimental drug called ADX-324 in 90 adults with hereditary angioedema (HAE) types 1 or 2. HAE causes sudden, painful swelling in the body. ADX-324 uses a technology called siRNA to lower levels of a protein involved in triggering these attacks.…
Phase 3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Botox injections could tame painful skin disease
Disease control Recruiting nowThis study is testing whether Botox injections can reduce inflammation in people with hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. Researchers believe that blocking certain nerve signals may calm the immune response. The study will enroll 20 …
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for Hard-to-Treat skin cancer: PTX-100 enters phase 2 trial
Disease control Recruiting nowThis phase 2 trial tests a drug called PTX-100 in 115 adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants receive PTX-100 by IV infusion over several cycles. The goal is to see if the drug can shrink or eliminate tumors an…
Phase 2 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New injection aims to heal skin ulcers in rare disease
Disease control Recruiting nowThis phase 2 trial tests an injection called SHR-1139 in 10 adults with ulcerative pyoderma gangrenosum, a rare skin condition that causes painful, open sores. The main goal is to see if the drug can completely close the target ulcer within 12 weeks. Researchers will also check f…
Phase 2 • Sponsor: Shandong First Medical University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill could tame stubborn hives
Disease control Recruiting nowThis study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Partic…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new daily pill quiet the immune attack behind psoriasis?
Disease control Recruiting nowThis phase 3 trial is testing an experimental daily capsule called TQH3906 in adults with moderate to severe plaque psoriasis. The drug works by blocking a key immune pathway involved in skin inflammation. Researchers are comparing TQH3906 against a placebo and an approved treatm…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for painful skin condition: drug trial targets chinese patients
Disease control Recruiting nowThis study tests a drug called secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils and tunnels under the skin. The goal is to see if the drug reduces skin lesions and prevents flare-ups over 16 weeks. About 36…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for vitiligo: experimental drug aims to bring back skin color
Disease control Recruiting nowThis study tests an experimental drug called GIA632 in 210 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the drug can safely restore skin color and to find the best dose for future studies. Participants will receive e…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a lupus drug protect lungs in connective tissue disease?
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of belimumab in adults with lung scarring (interstitial lung disease) caused by systemic sclerosis or other connective tissue diseases. About 514 people who completed earlier trials will receive belimumab for up to severa…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New radioactive drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug trial aims to tame hardening skin and lung damage in scleroderma
Disease control Recruiting nowThis study tests whether the drug ianalumab can help people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and can damage internal organs like the lungs. About 200 adults will receive either ianalumab or a placebo as a shot under the skin. Rese…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Psoriasis drug risankizumab under Real-World spotlight for quality of life boost
Disease control Recruiting nowThis study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will track changes in quality of life, including skin symptoms and daily impacts, over up to 2.5 years. The goal is to see how well the drug…
Sponsor: AbbVie • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a laser beam heal stubborn leg wounds?
Disease control Recruiting nowThis study tests whether shining a special low-level laser on chronic leg ulcers can help them heal faster. 96 adults with venous leg ulcers will receive either real laser treatment plus standard compression, or a sham laser plus compression, twice a week for 16 weeks. The goal i…
Sponsor: University of Nove de Julho • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody drug takes aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Wearable sensor could take the guesswork out of leg ulcer treatment
Disease control Recruiting nowThis study tests a wearable device called Tight Alright that measures pressure under compression bandages for venous leg ulcers. Standard compression therapy is effective but hard to get right without feedback. The device sends pressure data to a phone app, helping clinicians and…
Sponsor: Feeltect Limited • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill could clear skin in kids with psoriasis – trial underway
Disease control Recruiting nowThis phase 3 trial tests whether zasocitinib, an oral medication, can safely and effectively treat moderate-to-severe plaque psoriasis in children and teens aged 4 to 17. The study involves 110 participants and lasts up to 4 years. In the first part, some receive the drug and oth…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for kids with severe hair loss: baricitinib pill tested in major trial
Disease control Recruiting nowThis study tests whether baricitinib, a daily pill, can safely regrow hair in children aged 6 to 17 with severe alopecia areata (patchy hair loss). About 595 kids will receive either the drug or a placebo for 36 weeks, then all can get the drug for up to 2 years. The goal is to s…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot aims to recolor white patches in vitiligo
Disease control Recruiting nowThis study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the …
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot aims to tame rare autoimmune disease
Disease control Recruiting nowThis early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…
Phase 1/2 • Sponsor: Prolium Bioscience, Inc • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot could tame severe eczema in teens
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called SHR-1819 in about 200 teenagers aged 12 to 17 with moderate-to-severe atopic dermatitis (eczema). Participants receive either the drug or a placebo injection. The study measures how well the drug clears skin rashes and reduces …
Phase 3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Cream-and-Steroid combo aims to recolor vitiligo patches
Disease control Recruiting nowThis study tests whether a cream containing ruxolitinib (Opzelura) combined with corticosteroid injections or pills can improve facial vitiligo. It includes people aged 12 and older with active, non-segmental vitiligo affecting the face. Participants use the cream twice daily and…
Sponsor: ShanShan Li • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase 1/2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New IV drug hopes to regrow hair in severe alopecia
Disease control Recruiting nowThis study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo intravenously. The goal is to see if the drug can regrow hair and to check for side effe…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot could tame tough eczema by calming overactive immune cells
Disease control Recruiting nowThis study tests an experimental drug called rezpegaldesleukin (NKTR-358) for people aged 12 and older with moderate-to-severe atopic dermatitis, a type of eczema. Participants receive either the drug or a placebo as a shot under the skin. The goal is to see if the drug can clear…
Phase 3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New eczema drug shows promise in Long-Term trial
Disease control Recruiting nowThis study is for people with moderate-to-severe eczema who have already completed a previous APG777 trial. It aims to see if APG777 is safe and works well over a longer period. Participants will receive injections of the drug every 12 or 24 weeks and be monitored for side effect…
Phase 2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for stiff lungs? drug trial targets scarring from autoimmune disease
Disease control Recruiting nowThis phase 3 trial tests whether belimumab (Benlysta) can stabilize or improve lung function in adults with interstitial lung disease caused by connective tissue diseases like rheumatoid arthritis or lupus. About 440 participants will receive either belimumab injections or a plac…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a lupus drug help scleroderma lungs?
Disease control Recruiting nowThis study tests whether belimumab (Benlysta), a drug already used for lupus, can improve lung function and skin thickening in adults with scleroderma-related interstitial lung disease. About 300 participants will receive either belimumab or a placebo added to their standard care…
Phase 2/3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Lab-Grown immune cells take on dangerous viruses in vulnerable patients
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cream could help kids with 'Butterfly Skin' heal faster
Disease control Recruiting nowThis phase 3 trial tests whether a cream called SD-101 can help close wounds in children with epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. About 80 children aged 1 month to 12 years will apply the cream or a placebo to their whole body for 2 month…
Phase 3 • Sponsor: Paradigm Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Eczema drug afimkibart tested for Long-Term safety in new study
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug afimkibart for people with atopic dermatitis (eczema) who have already taken it in earlier studies. About 120 adults will be followed to see how well the drug controls their eczema over time and what side effe…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New eczema drug shows promise for kids in Late-Stage trial
Disease control Recruiting nowThis study tests whether abrocitinib, a liquid medicine, can improve moderate-to-severe eczema in children aged 6 to 12. About 150 kids will be randomly assigned to receive either the drug or a placebo for 16 weeks. The goal is to see if the medicine clears the skin and reduces i…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a diet tame chronic hives in teens?
Disease control Recruiting nowThis trial asks whether adding a Mediterranean diet or a low-histamine diet to standard care can reduce disease activity and improve quality of life in teens aged 12-18 with chronic spontaneous urticaria (CSU), a condition causing persistent hives. Participants are randomly assig…
Sponsor: Saglik Bilimleri Universitesi • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Weight-Loss drug tirzepatide could double as psoriasis treatment in new trial
Disease control Recruiting nowThis study is testing whether adding the weight-loss drug tirzepatide to the standard psoriasis medication ixekizumab helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 200 adults will receive tirzepatide injections for up to 12 months. …
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Bone transport device aims to heal chronic leg ulcers
Disease control Recruiting nowThis study is testing a device called the TrueLok Elevate that uses a technique called transverse bone transport to help heal chronic lower limb ulcers. The device is attached to the leg and slowly moves a piece of bone to stimulate blood flow and tissue healing. Researchers will…
Sponsor: Orthofix s.r.l. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer
Disease control Recruiting nowThis phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—in people with advanced sarcomas that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors or s…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for advanced cancers? pfizer launches early trial of PF-08046033
Disease control Recruiting nowThis early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill combo aims to fight advanced cancers that stopped responding to prior therapies
Disease control Recruiting nowThis study tests two oral drugs, AMXT 1501 and DFMO, given alongside standard treatments for people with advanced solid tumors (breast cancer or melanoma) that have worsened after prior therapies. The goal is to find a safe dose and see if the combination helps shrink tumors or s…
Phase 1/2 • Sponsor: Aminex Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New liquid drug offers hope for kids with severe eczema
Disease control Recruiting nowThis 24-month study tests the long-term safety and effectiveness of abrocitinib, a liquid oral medication, in children aged 2 and older with moderate-to-severe atopic dermatitis (eczema). About 500 participants will receive the drug, with or without topical creams. The goal is to…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New RNA drug shows promise in preventing HAE attacks in ongoing study
Disease control Recruiting nowThis study is for people with hereditary angioedema (HAE) who have already completed a previous trial of the drug ADX-324. ADX-324 is an RNA-based medicine designed to lower a protein involved in swelling attacks. The goal is to see if long-term use is safe and can reduce the num…
Phase 3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New psoriasis drug ORKA-001 tested for Long-Term safety
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. It is an open-label extension, meaning everyone gets the drug, and it includes 240 adults who already completed a previous trial with ORKA-0…
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can olive oil and nuts tame psoriasis? new study tests diet plus biologics
Disease control Recruiting nowThis study tests whether adding a Mediterranean diet (rich in olive oil, nuts, fish, and limited red meat) improves psoriasis symptoms in 36 adults who are about to start biologic therapy (Anti-IL-17 or Anti-IL-23 drugs). Participants are randomly assigned to either follow the di…
Sponsor: University Hospitals Cleveland Medical Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can radiofrequency waves outperform acne gels?
Disease control Recruiting nowThis trial tests whether a radiofrequency device can reduce inflammatory acne lesions as effectively as a standard topical gel. About 60 adults with mild-to-moderate facial acne will be randomly assigned to receive either three radiofrequency sessions or daily application of a co…
Sponsor: Jeisys Medical Inc • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new injection calm severe eczema when creams fall short?
Disease control Recruiting nowThis study tests whether an investigational drug called tilrekimig, given as injections alongside medicated creams or ointments, can improve moderate-to-severe eczema (atopic dermatitis) in people aged 12 and older. Participants will be randomly assigned to receive either tilreki…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a blister beetle extract banish common warts? phase 3 trial investigates
Disease control Recruiting nowThis Phase 3 trial tests YCANTH, a topical solution containing cantharidin (a substance from blister beetles), against a placebo for treating common warts. About 300 people aged 2 and older with at least one wart on their body (excluding certain areas) will receive either the act…
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody drug aims to regrow hair – first human trial underway
Disease control Recruiting nowThis early-stage trial tests whether ABS-201, an antibody that blocks a hormone receptor, is safe for treating hair loss. It starts with healthy volunteers and then includes people with male or female pattern baldness. Participants receive either the drug or a placebo and are mon…
Phase 1/2 • Sponsor: Absci Pty Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Four-Times-a-Year injection regrow hair in men?
Disease control Recruiting nowThis phase 3 trial tests an investigational drug called CKD-843 in men aged 18 to 50 with androgenetic alopecia, commonly known as male pattern baldness. Participants receive either CKD-843, a placebo, or the existing oral medication dutasteride for 12 months. Researchers measure…
Phase 3 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Poop pills aim to treat painful skin disease
Disease control Recruiting nowThis early study tests whether taking capsules containing donor fecal bacteria can change the gut and skin bacteria of people with hidradenitis suppurativa (HS), a painful skin condition. Sixteen adults with HS will receive either the bacteria capsules or a placebo for three week…
Early phase 1 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
One-Week radiation shows promise for breast cancer patients
Disease control Recruiting nowThis study tests a new, ultra-short radiation schedule for early-stage breast cancer. Instead of the usual 3 weeks, patients receive 5 radiation sessions over one week, with an extra boost to the tumor site given at the same time. The goal is to see if this approach is safe, redu…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a beam of light banish toenail fungus?
Disease control Recruiting nowThis trial tests whether photodynamic therapy (PDT) can clear toenail fungus. People with a confirmed fungal nail infection will have a special gel applied to the affected nail, then exposed to red light. The study will check if the nail looks healthy and if the fungus is gone at…
Phase 1 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Phase 1/2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Fasting during chemo: a new way to boost treatment?
Disease control Recruiting nowThis trial tests whether time-restricted eating (TRE) — a 16:8 fasting schedule — is feasible for patients with HER2-negative breast cancer undergoing neoadjuvant chemotherapy. Participants will follow TRE for 16 weeks while receiving chemo, and researchers will measure how many …
Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for painful skin condition: experimental drug aims to reduce abscesses
Disease control Recruiting nowThis study tests an experimental drug called SAR445399 in 144 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes abscesses and tunnels under the skin. Participants will receive one of two doses of the drug or a placebo for 32 weeks.…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill could clear psoriasis in teens
Disease control Recruiting nowThis study tests a daily pill called deucravacitinib in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. About 366 participants will receive either the drug or a placebo. The main goals are to see if the drug improves skin clearance by at least 75% and reduces ov…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a single cell therapy calm multiple autoimmune diseases?
Disease control Recruiting nowThis trial tests an investigational cell therapy called FT839 in people with active autoimmune diseases, including ANCA-associated vasculitis, inflammatory myositis, rheumatoid arthritis, lupus, and systemic sclerosis. Participants receive FT839 as two intravenous infusions, some…
Phase 1/2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for kids with rare swelling disorder as drug trial begins
Disease control Recruiting nowThis study tests a drug called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and how it works in young bodies. Researchers will monitor side effects and measure h…
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug hopes to heal painful skin ulcers in rare disease
Disease control Recruiting nowThis study tests whether spesolimab, given as an infusion, can help close skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory skin condition. About 90 participants will receive either spesolimab or a placebo, along with corticosteroids. The trial lasts about 1.5 …
Phase 3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One spot, many warts: heat and peroxide may trigger a full clearance
Disease control Recruiting nowThis trial tests a two-part approach for viral warts: applying mild heat at 44°C to the largest wart and using a 3% hydrogen peroxide solution on all warts. The idea is that heating one lesion may rally the immune system to fight the virus elsewhere, while the peroxide works dire…
Sponsor: First Hospital of China Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo therapy hopes to tackle rare skin cancer
Disease control Recruiting nowThis phase II trial tests whether combining a targeted antibody drug (mogamulizumab) with a procedure that treats white blood cells with light (extracorporeal photopheresis) can better control erythrodermic cutaneous T-cell lymphoma, a rare skin cancer. About 34 adults with advan…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Vacuum dressing could cut infections after skin graft surgery
Disease control Recruiting nowThis study tests whether a vacuum dressing (negative pressure wound therapy) reduces infection compared to standard bandages after skin graft surgery for leg tumors. About 242 adults will be randomly assigned to one of the two dressings. The main goal is to see if the vacuum dres…
Sponsor: Region Skane • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a new drug help kids regrow hair? major trial underway
Disease control Recruiting nowThis study tests if dupilumab can help children aged 6 to 17 with moderate to severe alopecia areata regrow hair. About 76 participants will receive either the drug or a placebo for 48 weeks, followed by an open-label extension. The main goal is to measure changes in scalp hair l…
Phase 2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a daily pill stop keloids from coming back?
Disease control Recruiting nowThis study tests whether the drug ritlecitinib can prevent keloids from returning after surgical removal. Keloids are raised, often itchy scars that grow beyond the original wound. The trial will enroll 30 adults who will take a daily pill for 36 weeks. Researchers will measure k…
Phase 2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Blood test could spare thousands from unnecessary breast cancer treatment
Disease control Recruiting nowThis study is testing whether a simple blood test that looks for cancer DNA can help doctors decide when to start a targeted therapy (CDK4/6 inhibitor) in people with intermediate-risk HR+ HER2- breast cancer. About 725 participants will have their blood tested every 3 months for…
Sponsor: Natera, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Last-Resort access to dupilumab for patients with severe inflammation
Disease control Expanded accessThis program provides compassionate use of dupilumab (Dupixent) for patients with severe type 2 inflammatory disorders who have no other treatment options. It aims to offer access to this drug outside of a clinical trial. The program is already approved for marketing.
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot could tame painful skin condition
Disease control Recruiting nowThis early-phase trial tests siplizumab, a drug given as a shot under the skin, in 12 adults with moderate-to-severe hidradenitis suppurativa (painful boils) that hasn't improved with standard treatments. The main goal is to see if the drug safely reduces the number of inflamed l…
Early phase 1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New daily pill could stop debilitating swelling attacks in HAE patients
Disease control Recruiting nowThis Phase 3 study tests a once-daily pill called deucrictibant to prevent swelling attacks in people aged 12 and older with hereditary angioedema (HAE). The trial will enroll 170 participants and monitor safety and attack rates over a long period. Unlike a cure, patients would n…
Phase 3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a skin lotion tame the symptoms of a rare genetic disease?
Disease control Recruiting nowThis trial tests whether QRX003, a lotion applied to the skin, can reduce the redness, scaling, and itch caused by Netherton syndrome, a rare genetic condition. Participants apply the lotion twice daily for 3 months and visit the clinic every 4 to 6 weeks for checkups. The study …
Phase 2/3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new injection quiet the painful lumps of hidradenitis suppurativa?
Disease control Recruiting nowThis trial tests an investigational drug called ORKA-002 in adults with moderate-to-severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps and tunnels under the skin. Participants receive either ORKA-002 or a placebo by injection, and researchers meas…
Phase 2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for kidney transplant patients with advanced skin cancer
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a lotion calm the severe skin symptoms of netherton syndrome?
Disease control Recruiting nowThis trial tests whether QRX003 lotion, applied to the skin, can safely reduce the severity of Netherton syndrome, a rare genetic condition causing red, scaly skin and intense itching. Researchers will enroll about 20 people aged 14 and older who have the condition. Participants …
Phase 2/3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New combo aims to keep prostate cancer in check with lower chemo dose
Disease control Recruiting nowThis study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…
Phase 2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
A pill that fights warts from the inside: trial puts immune-regulating capsule to the test
Disease control Recruiting nowThis trial tests whether a daily oral capsule called 2LVERU can clear common, flat, or plantar warts caused by HPV. Researchers compare the capsule against a placebo in 162 people aged 3 and older over 6 months. The main question is whether warts disappear completely by the end o…
Phase 4 • Sponsor: Labo'Life • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New cream shows promise for painful hand and foot pustules
Disease control Recruiting nowThis study tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis, a skin condition causing painful pus-filled blisters on hands and feet. About 135 adults will apply the cream twice daily for 16 weeks. The main goal is to see if the cream reduce…
Phase 2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a switch to guselkumab clear stubborn psoriasis?
Disease control Recruiting nowThis study looks at how well guselkumab works for people with moderate to severe psoriasis who switch from ustekinumab (or its biosimilar) in a real-world setting. Researchers will track skin clearance using the PASI score at various time points over a year. The goal is to see if…
Sponsor: Janssen-Cilag Kft. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Psoriasis patients monitored for two years on newer biologic drug
Disease control Recruiting nowThis study watches 200 adults with moderate-to-severe plaque psoriasis who have never taken a biologic before. They are starting treatment with guselkumab, and researchers will track how many continue the drug for two years. The goal is to see how well people stick with this trea…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a pill calm the skin symptoms of sarcoidosis?
Disease control Recruiting nowThis trial investigates whether an oral medication called brepocitinib can safely reduce skin lesions in adults with cutaneous sarcoidosis, a condition where inflammation causes bumps and rashes on the skin. Participants will receive either brepocitinib or a placebo to compare ef…
Phase 2/3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
One pill may halt sleeping sickness spread
Disease control Recruiting nowThis trial tests whether giving a single dose of acoziborole to people who test positive for sleeping sickness antibodies, but show no active infection, can stop the disease from spreading in a community. Researchers will screen entire villages and treat all seropositive individu…
Phase 3 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a simple patch stop diabetes device skin woes?
Disease control Recruiting nowThis trial tests whether a silicone-based or a hydrocolloid patch placed under insulin pumps or glucose monitors can prevent contact dermatitis from coming back in children aged 2-18. Participants will use different patches and attend visits for skin exams, ultrasounds, and quest…
Sponsor: Steno Diabetes Center Copenhagen • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can getting kids moving sooner in the ICU shorten their time on a ventilator?
Disease control Recruiting nowThis study tests a program called PICU Up! that helps critically ill children start moving earlier while in the pediatric intensive care unit. The program includes daily activity plans, better sedation management, and family involvement. Researchers want to see if this approach r…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Pineapple enzyme gel could speed healing of stubborn leg wounds
Disease control Recruiting nowThis study tests a gel called EscharEx, made from pineapple enzymes, to remove dead tissue from hard-to-heal leg ulcers. About 216 adults with venous leg ulcers will receive either the active gel or a placebo. The goal is to see if the gel safely and effectively cleans the wound …
Phase 3 • Sponsor: MediWound Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Stop the pills when symptoms vanish? landmark trial for Kids' infections
Disease control Recruiting nowThis study tests whether children with bacterial infections like urinary tract infections, cellulitis, or pneumonia can safely stop oral antibiotics once their symptoms go away, instead of finishing the entire course. About 200 children aged 1 to 17 who have already received IV a…
Phase 4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically…
Phase 1/2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can artificial intelligence stop bedsores before they start?
Disease control Recruiting nowThis trial tests whether an artificial intelligence app called PRESS AI can help nurses prevent pressure injuries (bedsores) in adult intensive care patients. The app supports nurses in assessing risk, staging wounds, and planning care. Researchers will compare the rate of new pr…
Sponsor: Ankara Yildirim Beyazıt University • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New Pill-and-Immunotherapy combo aims to shrink melanoma before surgery
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting pill (PRTX007) to standard immunotherapy (pembrolizumab) before surgery can improve outcomes for people with stage III melanoma. About 48 adults with resectable melanoma will take the combination for 9 weeks …
Phase 2 • Sponsor: Primmune Therapeutics, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a tiny biopsy outsmart skin Cancer's spread?
Disease control Recruiting nowThis trial tests whether removing and examining the sentinel lymph node—the first node a skin cancer might spread to—can catch metastasis earlier than standard monitoring. Half of the 142 participants with high-risk cutaneous squamous cell carcinoma will receive the biopsy plus s…
Sponsor: Germans Trias i Pujol Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New pill could regrow hair in severe alopecia – trial begins
Disease control Recruiting nowThis study tests a drug called deuruxolitinib in Japanese adults aged 18-65 with severe alopecia areata, an autoimmune condition causing significant scalp hair loss. Participants must have at least 50% hair loss. The trial measures how well the drug regrows hair and how satisfied…
Phase 3 • Sponsor: Sun Pharma Japan Limited • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New shot could help eczema sufferers who Don't respond to steroids
Disease control Recruiting nowThis Phase 3 study tests whether lebrikizumab, an injectable drug, can safely and effectively treat nummular eczema in adults who haven't gotten enough relief from topical steroids or can't use them. About 270 participants will receive either lebrikizumab or a placebo injection. …
Phase 3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Psoriasis drug may be safe for patients with fatty liver
Disease control Recruiting nowThis study looks at how long adults with plaque psoriasis and a common liver condition called MASLD (fatty liver disease) continue taking the drug secukinumab. Researchers will review medical records from several Spanish hospitals to track treatment duration and changes in liver …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug shows promise for severe eczema in toddlers
Disease control Recruiting nowThis study tests a drug called nemolizumab in toddlers aged 6 to 23 months with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams or ointments. The goal is to see how the drug moves through the body, if it is safe, and if it helps control the conditio…
Phase 2 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a drug calm severe eczema itch when the rash is mild? a new study investigates
Disease control Recruiting nowThis study looks at teenagers aged 12 to 17 who have severe atopic dermatitis (eczema) with intense itching but only a mild to moderate rash. They are being treated with dupilumab (Dupixent), a standard medication. The goal is to see how well dupilumab controls itching, improves …
Sponsor: Sanofi • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase 1/2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Brain training targets impulse control to fight OCD and related disorders
Disease control Recruiting nowThis study tests whether a computerized training program designed to improve response inhibition — the ability to stop an automatic action — can reduce symptoms in people with obsessive-compulsive disorder, trichotillomania (hair-pulling), or skin-picking disorder. Participants a…
Sponsor: University of Wisconsin, Milwaukee • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Microscopic skin scans may reveal how a new eczema drug reshapes the skin
Disease control Recruiting nowThis study tests whether reflectance confocal microscopy (RCM), a noninvasive imaging technique, can detect structural changes in the skin of people with moderate-to-severe atopic dermatitis (eczema) who are treated with nemolizumab. Nemolizumab is an antibody that blocks IL-31, …
Sponsor: Hôpitaux Drôme Nord • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Recruiting nowThis early study tests a new treatment called CD19/BCMA CAR-T for people with severe autoimmune diseases like lupus and Sjögren's syndrome that haven't improved with standard care. The treatment involves taking a patient's own immune cells, modifying them to target specific immun…
Sponsor: Liang Zou • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Skipping the armpit: a trial tests whether partial breast radiation alone is enough
Disease control Recruiting nowThis pilot study is testing whether partial breast irradiation alone — without first removing or sampling lymph nodes from the armpit — is safe for women age 40 and older with early-stage invasive breast cancer. All participants have had a lumpectomy but no sentinel node biopsy o…
Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Gene therapy gel targets rare blistering skin disease
Disease control Recruiting nowThis early study tests a new gene therapy gel called KB111 for Hailey-Hailey disease, a rare genetic condition that causes painful blisters and skin lesions. The gel uses a modified virus to deliver a working copy of the faulty gene directly to the skin. The trial enrolls about 7…
Early phase 1 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Custom breast shell could make radiation therapy faster and more comfortable
Disease control Recruiting nowThis trial tests whether a custom-made breast holder called VENUS SHELL™ can improve positioning and comfort during radiotherapy for early-stage breast cancer. Participants lie on their stomach while the device holds the breast in place, aiming to deliver precise radiation in sho…
Sponsor: HeroSupport SA • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Immune cells supercharged to fight advanced cancers
Disease control Recruiting nowThis study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…
Phase 1/2 • Sponsor: Obsidian Therapeutics, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New pill could help restore skin color in vitiligo patients
Disease control Recruiting nowThis study tests an experimental drug called D-2570 in 160 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take either D-2570 or a placebo pill once daily for 24 weeks, with an optional 24-week extension. The goal is to see if t…
Phase 2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Vitamin e dressing may speed healing of bedsores
Disease control Recruiting nowThis trial tests whether a special dressing containing tocotrienols (a form of vitamin E) helps heal stage 1 and 2 pressure ulcers (bedsores) faster than standard care. About 114 adults with pressure ulcers will be randomly assigned to receive either the tocotrienol dressing or a…
Sponsor: Monash University Malaysia • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New wound dressings aim to heal stubborn diabetic and leg ulcers
Disease control Recruiting nowThis trial investigates whether two special wound dressings—one made from donated amniotic membrane and another from a synthetic material—can help heal diabetic foot ulcers and venous leg ulcers that have not responded to standard care. Adults aged 18 and older with these hard-to…
Sponsor: Capsicure, LLC • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Battle of the bands: which hemorrhoid treatment wins?
Disease control Recruiting nowThis study compares two standard treatments for bleeding internal hemorrhoids: hemorrhoidal artery embolization (HAE) and rubber band ligation (RBL). HAE uses a catheter to block blood flow to the hemorrhoid with tiny particles or coils, while RBL uses rubber bands to cut off cir…
Sponsor: Jessica K. Stewart, MD • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New pill could clear psoriasis skin in 12 weeks
Disease control Recruiting nowThis Phase 2 trial tests an experimental oral drug called D-2570 in 75 adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either D-2570 or a placebo tablet for 12 weeks. The main goal is to see if the drug can achieve at least a 90% imp…
Phase 2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New pill could stop scalp scarring and hair loss
Disease control Recruiting nowThis study tests an oral medication called brepocitinib for adults with lichen planopilaris, a condition that causes scalp inflammation, scarring, and hair loss. About 342 participants will receive either the drug or a placebo to see if it reduces symptoms and improves scalp appe…
Phase 2/3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a histamine shot tame chronic hives?
Disease control Recruiting nowThis study looks at how well an injection called Immunoglobulin-Histamine complex (IHC, brand name Histoglob) works for people with chronic urticaria, or long-term hives. Researchers will track 600 patients in India to see if the treatment reduces hives and the need for other all…
Sponsor: Bharat Serums and Vaccines Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells take aim at blistering skin disease
Disease control Recruiting nowThis study investigates whether a single infusion of a patient's own genetically modified immune cells (CD19 CAR-T cells) can safely control moderate-to-severe pemphigus vulgaris that hasn't responded to standard treatments. The therapy targets and depletes B cells, which are tho…
Sponsor: Jinbo Chen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can supplements boost healing after gum color surgery?
Disease control Recruiting nowThis study looks at whether taking coenzyme Q10 and vitamin C, alone or together, can improve healing and reduce dark gum color after surgical gum depigmentation. The trial involves 20 healthy adults with dark gums who undergo a simple scalpel procedure to remove pigmented tissue…
Sponsor: Al-Azhar University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New eczema drug enters first human trials
Disease control Recruiting nowThis study is the first time REGN20423 is being tested in humans. It will enroll 144 adults, first healthy volunteers and then people with atopic dermatitis (eczema). The goal is to check safety, side effects, how the drug moves through the body, and whether it helps eczema sympt…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Can 'Supercharged' donor cells beat viruses that drugs Can't?
Disease control Recruiting nowThis study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure …
Phase 1/2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for bedsores: 2,000-Patient trial tests advanced wound matrices
Disease control Recruiting nowThis study tests whether adding special wound dressings (called CAMPs) to standard care helps heal pressure ulcers (bedsores) that won't close on their own. About 2,000 adults with stage 3 or 4 pressure sores will receive weekly applications of a CAMP product plus standard care, …
Phase 4 • Sponsor: Sequence LifeScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a simple ointment replace surgery for some skin cancers?
Disease control Recruiting nowThis study tests whether an ointment called tirbanubulin can effectively treat superficial basal cell carcinoma, a common type of skin cancer. Adults with small, previously untreated lesions on the body (not the face or scalp) apply the ointment once daily for five days. If the l…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a five-day ointment improve sun-damaged skin? new study investigates
Disease control Recruiting nowThis study follows adults with actinic keratosis (precancerous sun-damaged spots) on the face who are already using tirbanibulin ointment as part of their regular care. Researchers want to see if the treatment improves overall skin appearance and texture over 57 days. Participant…
Sponsor: Avant Health LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Bioactive glass may help seal the ear after cholesteatoma surgery
Disease control Recruiting nowThis trial tests whether a bioactive glass material can effectively fill the mastoid bone after surgery for cholesteatoma, a non-cancerous but destructive ear growth. Adults having their first cholesteatoma operation will receive the glass filler to stabilize the repair and preve…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New gel could tackle stubborn yeast infections
Disease control Recruiting nowThis study tests a new gel called OCF001 for treating acute yeast infections in women. About 36 women with a confirmed yeast infection will use the gel or a placebo for 7 days. Researchers will check if the infection clears up and if the gel is safe and well-tolerated.
Phase 2 • Sponsor: Sano Chemicals Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AB821 enters first human tests for advanced melanoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.
Phase 1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
One-Week radiation for breast cancer: MRI precision may cut side effects
Disease control Recruiting nowThis study tests a new radiation approach for early breast cancer that uses real-time MRI guidance to deliver just three high-dose sessions over one week, instead of the usual several weeks. The goal is to see if this shorter treatment is safe, preserves the breast's appearance, …
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Drug combo aims to halt lung scarring in scleroderma
Disease control Recruiting nowThis trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…
Phase 3 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Heat treatment could bring leishmaniasis care to local clinics
Disease control Recruiting nowThis study tests whether using a device that heats skin lesions to 50°C for 30 seconds can effectively treat cutaneous leishmaniasis in primary health centers in Ethiopia. 103 patients aged 12 to 60 with up to four lesions will receive thermotherapy and be monitored for 90 days. …
Sponsor: Armauer Hansen Research Institute, Ethiopia • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can stem cells heal burn scars? new trial aims to find out
Disease control Recruiting nowThis study tests whether injections of stem cells from donated fat tissue can improve the quality of old burn scars. 39 adults with hypertrophic scars (at least 2 years old) will receive stem cells in one scar area and a placebo in another. The main goal is to see if patients rep…
Phase 1/2 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered immune cells take on Hard-to-Treat melanoma
Disease control Recruiting nowThis study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for rare muscle disease: baricitinib trial aims to cut steroid use
Disease control Recruiting nowThis Phase 3 trial tests whether baricitinib, a JAK inhibitor pill, can improve symptoms of dermatomyositis (a rare autoimmune disease causing muscle weakness and skin rashes) while allowing patients to stop steroids. 62 adults with active disease will receive baricitinib or a pl…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Natural prebiotic could beat antibiotics for thrush and BV
Disease control Recruiting nowThis study tests whether lactoferrin, a natural prebiotic from cow's milk, can be a good alternative to antibiotic tablets for women with bacterial vaginosis (BV) or thrush. Researchers will recruit 114 women and give half lactoferrin vaginal pessaries for 3 weeks, while the othe…
Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a 2-Week radiation course replace longer treatment for skin cancer?
Disease control Recruiting nowThis study tests whether a short course of radiation (5 treatments over 2 weeks) can prevent cancer from coming back in people with high-risk head and neck skin cancer after surgery. For those with moderate-risk cancer, researchers want to see if simply monitoring them closely is…
Phase 2 • Sponsor: University of Vermont Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a stronger acne drug be better for darker skin? new trial aims to find out
Disease control Recruiting nowThis study compares giving oral isotretinoin (a strong acne medication) right away versus the usual antibiotics for moderate acne in people with darker skin (Fitzpatrick types IV-VI). The goal is to see if early use of isotretinoin reduces acne-related dark spots better than stan…
Phase 3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Placental grafts show promise for stubborn diabetic foot sores
Disease control Recruiting nowThis study tests whether a special placental graft, used alongside standard wound care, helps close diabetic foot ulcers that won't heal on their own. About 350 adults with type 1 or 2 diabetes and a foot ulcer between 1 and 15 cm² will be randomly assigned to get the graft plus …
Phase 4 • Sponsor: Sequence LifeScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a shorter antibiotic course be just as good for leg infections?
Disease control Recruiting nowThis phase 3 trial compares a 5-day course of the antibiotic flucloxacillin to the standard 7-day course for adults with leg cellulitis. About 334 participants will receive either 5 days of active drug plus 2 days of placebo, or 7 days of active drug. The goal is to see if the sh…
Phase 3 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New peptide serum takes on hair loss in head-to-head trial
Disease control Recruiting nowThis study compares a new peptide-based hair serum to the standard treatment minoxidil for people with pattern baldness. About 80 adults with mild to moderate hair loss will use one of the two treatments for 24 weeks. Researchers will measure changes in hair density and thickness…
Sponsor: Institute of Dermatology, Thailand • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Old drug, new hope: could filgotinib tame rare immune diseases?
Disease control Recruiting nowThis phase 2 trial is testing whether filgotinib, a drug already used for arthritis, can help people with three rare immune diseases: Behçet's disease, myositis, and IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term ster…
Phase 2 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could light and magnets finally heal stubborn leg wounds?
Disease control Recruiting nowThis study tests a device that uses light and magnets (COMS) to help heal chronic leg ulcers. About 122 people with venous leg ulcers will receive either standard care plus COMS or standard care alone. The goal is to see if the device speeds up wound healing and improves quality …
Phase 4 • Sponsor: Sebastian Probst • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThis study tests whether adding IV IgG treatment to standard VYJUVEK therapy can help wounds heal faster and reduce blistering in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin condition. Eight participants will receive IV IgG alongside their u…
Phase 1/2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for stubborn warts: extended treatment shows promise
Disease control Recruiting nowThis study follows people who already took part in earlier YCANTH wart studies. It tests whether up to 4 more treatments, applied every 21 days, can safely clear common warts. About 600 adults and children will be monitored for a year. The goal is to see if the medicine continues…
Phase 3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New program aims to cut risky drug mix-ups for kids on multiple medications
Disease control Recruiting nowThis study tests a program called Pediatric Medication Therapy Management (pMTM) for children with complex medical conditions who take five or more medications. The program involves a thorough review of all medicines, optimizing the regimen, and creating a clear medication plan. …
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New gel could ease painful skin growths
Disease control Recruiting nowThis phase 2 trial tests a gel called PTX-022 (sirolimus) on people aged 6 and older with angiokeratomas, which are small, raised skin spots. The study will check if the gel is safe and helps improve the appearance of these spots. Fifteen participants will apply the gel and be mo…
Phase 2 • Sponsor: Palvella Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Radiation or watchful waiting? new trial for aggressive skin cancer
Disease control Recruiting nowThis phase 3 trial compares two strategies for people with high-risk cutaneous squamous cell carcinoma after surgery: adding radiation therapy versus simply monitoring. About 266 participants will be randomly assigned to one of the two groups and followed for at least two years. …
Phase 3 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Landmark study questions blood thinner use in Behçet's clots
Disease control Recruiting nowThis study tests whether adding blood thinners (anticoagulants) to standard steroid treatment is better than steroids alone for deep vein clots in people with Behçet's syndrome. About 134 adults with a first or repeat clot will be randomly assigned to one of two groups. The goal …
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Antibiotic shots around wounds could speed healing in new trial
Disease control Recruiting nowThis phase 2 trial tests whether injecting antibiotics directly into the tissue around chronic wounds helps them heal better than standard care alone. About 60 adults with non-healing wounds on their legs, arms, or trunk will either receive the antibiotic injections plus usual wo…
Phase 2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radioactive drug plus immunotherapy shows promise for rare skin cancer
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and lutetium Lu 177 dotatate (a radioactive drug that kills cancer cells)—in 18 adults with Merkel cell carcinoma. The goal is to see if the combination can shri…
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Major trial questions need for extra surgery in melanoma patients
Disease control Recruiting nowThis study tests whether people with melanoma can safely avoid a second surgery (re-excision) after the initial tumor is removed with clear margins. About 1,749 adults with stage pT1b to pT4b melanoma will be randomly assigned to either standard follow-up care including re-excisi…
Phase 3 • Sponsor: Marieke Goodijk • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug cocktail aims to save lungs in scleroderma patients
Disease control Recruiting nowThis study tests whether combining two drugs, nintedanib and tocilizumab, works better than standard treatments (like mycophenolate) for people with systemic sclerosis (scleroderma) who also have lung scarring. The trial will enroll 86 adults and follow them for 56 weeks, measuri…
Phase 3 • Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Tiny needle patch takes aim at skin cancer
Disease control Recruiting nowThis study tests a small adhesive patch with tiny needles that deliver a low dose of the chemotherapy drug doxorubicin directly into skin cancer tumors. It involves 48 people with squamous cell skin cancer who are either immune-competent or immune-suppressed. The goal is to see i…
Phase 1/2 • Sponsor: Falo, Louis, MD • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New care pathways could improve life for rare disease patients
Disease control Recruiting nowThis study looks at whether offering personalized follow-up, including video visits, helps more people with pseudoxanthoma elasticum (PXE) get proper care. PXE causes calcium buildup in skin, eyes, and blood vessels, leading to vision loss and other problems. The researchers will…
Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …
Phase 1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a flower extract heal parasitic skin ulcers? new trial seeks answers
Disease control Recruiting nowThis phase 3 trial tests whether a plant-based tincture made from arnica flowers can safely and effectively heal skin ulcers caused by cutaneous leishmaniasis, a parasitic disease spread by sandflies. About 96 people aged 12 and older with confirmed infection will receive either …
Phase 3 • Sponsor: Universidad de Antioquia • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could an ancient remedy cut early deaths in leukemia?
Disease control Recruiting nowThis study tests whether giving a Chinese herbal medicine called Realgar-Indigo naturalis formula (RIF) together with standard vitamin A therapy right away can lower the risk of early death in people with a fast-growing blood cancer called acute promyelocytic leukemia (APL). Abou…
Phase 3 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells aim to tame childhood arthritis and lupus
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases lik…
Early phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
One shot before surgery: could early immunotherapy stop melanoma in its tracks?
Disease control Recruiting nowThis study is testing whether giving one dose of the immunotherapy drug pembrolizumab six weeks before surgery can help the immune system fight high-risk melanoma more effectively. About 49 adults with melanoma that hasn't spread on scans will receive the drug, then have their ly…
Phase 2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New injection targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…
Phase 1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Blood test may end guesswork in psoriasis dosing
Disease control Recruiting nowThis study tests whether measuring biologic drug levels in the blood can help doctors adjust doses for people with psoriasis. About 210 adults on certain biologics will either get dose advice based on blood tests or continue standard care. The goal is to maintain disease control …
Phase 4 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for genital eczema: drug trial targets severe itch and pain
Disease control Recruiting nowThis study tests whether tralokinumab, an approved eczema drug, can improve moderate-to-severe atopic dermatitis in the genital area. About 30 adults will receive the drug and be monitored for 52 weeks using special skin imaging and symptom questionnaires. The goal is to see if i…
Sponsor: University Hospital Schleswig-Holstein • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can advanced imaging reveal hidden swallowing muscle damage in IBM?
Diagnosis Recruiting nowResearchers at Johns Hopkins University are studying whether neuromuscular ultrasound and MRI can serve as reliable markers of swallowing muscle problems in people with inclusion body myositis (IBM). The study compares imaging and clinical findings in 30 participants, including p…
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Acne may signal hidden hormonal disorder in young women
Diagnosis Recruiting nowResearchers at Sohag University Hospital want to know how many women with acne also have polyendocrine metabolic ovarian syndrome, a hormonal and metabolic condition. The study enrolls 90 women aged 15 to 49 who have been diagnosed with acne. Doctors will check each participant f…
Sponsor: Sohag University • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New PET tracer aims to spot hidden cancer spread in the abdomen
Diagnosis Recruiting nowThis phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …
Phase 2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Blood test aims to catch Cancer's return earlier
Diagnosis Recruiting nowThe ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
New scan could spot Hard-to-Find breast cancer spread
Diagnosis Recruiting nowThis early-stage trial tests a new radioactive tracer called [68Ga]Ga DOTA-5G for PET/CT scans in 30 people with metastatic lobular breast cancer. The goal is to see if it can find cancer lesions better than current methods and to check its safety. Participants receive one inject…
Phase 1 • Sponsor: University of California, Davis • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Can a 12-Item quiz capture daily life with lipedema?
Diagnosis Recruiting nowResearchers are testing whether the Turkish version of the Duke Activity Status Index, a 12-item questionnaire about everyday activities, reliably measures functional capacity in women with lipedema. The study will enroll 34 women with the condition and compare their questionnair…
Sponsor: Istanbul University - Cerrahpasa • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
New screening tool aims to catch hidden arthritis in psoriasis patients
Diagnosis Recruiting nowThis Canadian study tests whether adding two questions about morning stiffness and lower back pain to a standard screening tool (PEST) can help dermatologists identify psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults who are candida…
Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Fast new swab test could speed up vaginitis diagnosis
Diagnosis Recruiting nowThis study will test a new diagnostic device called the Nanopath assay, which aims to quickly detect bacteria or yeast causing vaginitis. Up to 1000 women with symptoms like itching or discharge will provide vaginal swab samples, either collected by a clinician or themselves. The…
Sponsor: Nanopath, Inc • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
Could a scan replace surgery for breast cancer staging?
Diagnosis Recruiting nowThis study tests whether a special PET/MRI scan can accurately detect if breast cancer has spread to lymph nodes in the armpit, potentially replacing the need for surgical removal of those nodes. About 119 women with certain types of breast cancer (luminal A or lobular) will get …
Phase 2 • Sponsor: Università Vita-Salute San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Phone AI could spot eye disease in remote areas
Diagnosis Recruiting nowThis study tests a smartphone app that uses artificial intelligence to detect 16 different eye diseases from photos taken with the phone. The AI works entirely on the device, so no internet is needed. Researchers will compare its accuracy to eye doctors and see if non-medical use…
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New scan aims to uncover hidden breast cancer in early stage patients
Diagnosis Recruiting nowThis study tests a new imaging method called FAPI-PET/MRI to see if it can detect hidden invasive breast cancer in 30 people diagnosed with ductal carcinoma in situ (DCIS), a common pre-stage of breast cancer. Participants receive a weakly radioactive drug and lie in a scanner fo…
Phase 2 • Sponsor: Universität Münster • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New AI-Powered 'Eye' could slash repeat breast cancer surgeries
Diagnosis Recruiting nowThis study tests a new handheld device that uses light and artificial intelligence to check for leftover cancer cells right after a breast lump is removed. The goal is to help surgeons remove all cancer in one go, avoiding a second surgery. About 104 women having breast-conservin…
Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Can a phone app stop sunburns before they start?
Prevention Recruiting nowResearchers at the University of Utah are testing a mobile health app designed to help young adults protect their skin from the sun. The study enrolls 20 people aged 18 and older who have had at least one sunburn in the past year or who rarely use sun protection. For four weeks, …
Sponsor: University of Utah • Aim: Prevention
Last updated Sep 21, 2026 20:00 UTC
-
Could a tailored screening schedule beat annual mammograms?
Prevention Recruiting nowThis study compares annual mammograms to a personalized screening schedule based on each woman's breast cancer risk. Participants choose or are assigned to either annual screening or risk-based screening, which uses genetic testing and personal history. The goal is to see if pers…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Sep 21, 2026 20:00 UTC
-
Broccoli compound put to the test against melanoma
Prevention Recruiting nowResearchers are testing whether sulforaphane, a substance found in broccoli and other cruciferous vegetables, can prevent melanoma in people who have multiple atypical moles and a prior history of melanoma. Participants take sulforaphane or a placebo by mouth. The trial measures …
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Can a triple laser combo turn back sun damage and ward off skin cancer?
Prevention Recruiting nowThis trial tests whether combining three light-based treatments can improve sun-damaged facial skin and possibly help prevent skin cancer. Researchers will treat one side of each participant's face with a thulium laser, an Er:Glass laser, and intense pulsed light, while the other…
Sponsor: Merete Haedersdal • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Could a probiotic cream shield cancer patients from radiation burns?
Prevention Recruiting nowThis early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…
Phase 1 • Sponsor: West China Hospital • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Shingles sufferers: could this pill stop your pain from becoming chronic?
Prevention Recruiting nowThis study tests whether the oral medication venlafaxine, typically used for depression, can prevent postherpetic neuralgia—a persistent nerve pain that often follows a shingles rash. Researchers will enroll 832 adults who have had a shingles rash for less than 30 days and are ex…
Sponsor: Beijing Tiantan Hospital • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Can a baseball league program help prevent skin cancer in rural kids?
Prevention Recruiting nowThis study tests a sun protection program for children playing baseball in rural Utah and West Virginia. Researchers will observe whether kids on teams using the program apply sunscreen, wear hats and long sleeves, and seek shade more often than those on teams that don't. The goa…
Sponsor: University of Utah • Aim: Prevention
Last updated Aug 12, 2026 00:00 UTC
-
Blood thinner may stop autoimmune disease before it starts
Prevention Recruiting nowThis trial tests whether clopidogrel, a common blood thinner, can prevent systemic sclerosis (scleroderma) in people who have Raynaud phenomenon and specific antibodies that put them at high risk. About 47% of such individuals develop full scleroderma within five years. Participa…
Phase 2/3 • Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Kitchen staple may protect skin during surgery: paraffin oil tested against tourniquet burns
Prevention Recruiting nowThis study tests whether applying paraffin oil to the skin before using a tourniquet (a tight band that stops blood flow) during arm surgery can prevent skin injuries like redness, blisters, or burns. About 90 adults having elective upper arm surgery will be randomly assigned to …
Sponsor: Istanbul Medipol University Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:03 UTC
-
Shingles shot may shield seniors from heart attacks and dementia
Prevention Recruiting nowThis large study in Denmark is testing whether the shingles vaccine (Shingrix) can do more than prevent shingles—it may also lower the risk of heart attacks, strokes, and dementia. About 162,000 adults aged 65 and older will either get the vaccine or no vaccine, and researchers w…
Phase 4 • Sponsor: Tor Biering-Sørensen • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New balloon method aims to stop Post-C-Section bleeding in High-Risk moms
Prevention Recruiting nowThis study tests a new method called U-CaVIT, which uses a balloon placed in the uterus to prevent severe bleeding after a C-section in women at high risk. About 70 participants will either get standard care or standard care plus the balloon. The goal is to see if the balloon red…
Sponsor: Christian Haslinger • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Breakthrough trial aims to prevent arthritis in psoriasis patients
Prevention Recruiting nowThis study tests whether the drug guselkumab can prevent psoriatic arthritis in people with psoriasis who are at high risk. 176 adults with psoriasis and early signs of joint inflammation will receive either guselkumab or standard care. The goal is to see if the drug can stop art…
Phase 4 • Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Could licorice root be the next skin soother?
Symptom relief Recruiting nowThis study looks at whether a natural compound from licorice root, called glycyrrhetinic acid, can help calm irritated skin and repair the skin barrier. Researchers will apply a mild irritant to the skin of 30 healthy adults, then treat the area with a cream containing the compou…
Sponsor: University of Split, School of Medicine • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
New hives drug shows promise in early trial
Symptom relief Recruiting nowThis study tests a new medication called ARS-2 for people with chronic spontaneous urticaria (long-term hives). It aims to see if ARS-2 can quickly reduce itching and hives during flare-ups. The trial involves 42 adults who will receive either ARS-2 or a placebo during separate f…
Phase 2 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
A new gel aims to fade dark Spots—Will it deliver a brighter complexion?
Symptom relief Recruiting nowThis trial tests whether a depigmenting gel cream called Blancy Pro can reduce facial hyperpigmentation, including dark spots and melasma. Forty women aged 30 to 60 will apply the product daily for 90 days. Researchers will measure skin lightening using a colorimeter and clinical…
Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Smartwatch workouts aim to beat Post-Chemo fatigue
Symptom relief Recruiting nowThis study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…
Sponsor: Centre Antoine Lacassagne • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
One laser, many skin fixes? trial tests 1550nm device on scars and wrinkles
Symptom relief Recruiting nowResearchers are testing a 1550nm non-ablative fractional laser on adults with skin concerns such as acne scars, wrinkles, and dark spots. The trial enrolls about 200 people aged 18 to 70. Participants receive laser treatment, then answer questionnaires about their experience. Der…
Sponsor: AVAVA, Inc. • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New pill could stop the maddening itch of prurigo nodularis
Symptom relief Recruiting nowThis study tests an experimental drug called ICP-332 for people with prurigo nodularis, a skin condition causing many intensely itchy bumps. About 135 adults will receive either the drug or a placebo to see if it reduces itching and clears the bumps over 16 weeks. The goal is to …
Phase 2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Could almond oil beat a Skin-Lightening cream?
Symptom relief Recruiting nowThis study compares almond oil to hydroquinone cream for treating facial pigmentation in women with darker skin tones. Researchers will also check how each treatment affects the skin's microbiome. The goal is to see if almond oil is a safer, natural alternative to the standard tr…
Phase 4 • Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Could a citrus compound heal scleroderma finger ulcers?
Symptom relief Recruiting nowThis study tests whether diosmin, a citrus-based supplement, can safely heal open sores on the fingers of people with scleroderma. About 45 adults with at least one active digital ulcer will take either diosmin or a placebo for 8 weeks. Researchers will track ulcer healing, pain,…
Sponsor: Primus Pharmaceuticals • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New gel could help cancer patients ditch steroid creams
Symptom relief Recruiting nowThis study is testing whether a special gel called StrataCTX can help people with skin reactions from cutaneous T-cell lymphoma (CTCL) or cancer treatments use less steroid cream. Steroid creams can have side effects when used a lot, so finding an alternative is important. The st…
Sponsor: Columbia University • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
New eczema drug enters first human tests
Symptom relief Recruiting nowThis early-stage trial is testing a new injectable drug called ARQ-234 in healthy volunteers and people with moderate to severe eczema. The main goals are to check safety and how the body processes the drug, while also looking for early signs that it might improve eczema symptoms…
Phase 1 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a common plant compound help rare telomere disease?
Symptom relief Recruiting nowThis pilot study tests whether quercetin, a natural antioxidant found in many plants, is safe for people with Dyskeratosis congenita or telomere biology disorders. Twelve participants will take quercetin for 24 weeks while researchers monitor side effects and how well people stic…
Phase 1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can vitamin d speed healing of bed sores in the ICU?
Symptom relief Recruiting nowResearchers are testing whether high-dose vitamin D helps heal bed sores in patients admitted to intensive care units. The trial enrolls 50 critically ill adults with low vitamin D levels and grade 1 or 2 pressure ulcers. Participants receive 50,000 IU of vitamin D3 in milk daily…
Sponsor: Maha Salah • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Salt shaker showdown: could less sodium mean less eczema itch?
Symptom relief Recruiting nowThis study looks at whether lowering salt in your diet can make eczema less severe. Forty adults with eczema will eat a low-salt diet for 24 weeks. For 5 weeks they'll take salt pills, and for another 5 weeks they'll take placebo pills, to see the real effect of sodium. Researche…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a Self-Drainage routine match Therapist-Led care for lipedema?
Symptom relief Recruiting nowThis trial tests two six-week physiotherapy programs in women with lipedema, a condition that causes painful fat buildup in the legs. One group receives manual lymphatic drainage from a therapist plus supervised aerobic exercise. The other group learns self-lymphatic drainage and…
Sponsor: Merve SEVINC GUNDUZ • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Could a seawater balm soothe eczema as well as the gold standard?
Symptom relief Recruiting nowThis study compares a new emollient balm made from seawater (Relipid+) to a leading balm (Lipikar) for mild to moderate eczema in people aged 6 months to 70 years. The goal is to see if the new balm works just as well at reducing symptoms and improving skin health. Researchers wi…
Sponsor: University Hospital, Caen • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Could a Light-Up cap help women with a common scarring hair loss?
Symptom relief Recruiting nowThis small pilot study tests whether a special red LED cap can improve symptoms and slow hair loss in women with central centrifugal cicatricial alopecia (CCCA), a scarring hair loss that mainly affects middle-aged Black women. Five women with confirmed CCCA will use the cap dail…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New Real-World study tests nemolizumab for chronic itch condition
Symptom relief Recruiting nowThis study looks at how well the drug nemolizumab works for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. Researchers will track 600 participants over 6 months in real-world clinics, measuring itch severity and skin lesi…
Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New pill could tame stubborn hives
Symptom relief Recruiting nowThis early-stage trial tested an experimental oral drug called BGB-16673 in 34 adults with chronic spontaneous urticaria (CSU), a condition causing persistent hives and itching. The study was double-blind and placebo-controlled, meaning neither patients nor doctors knew who got t…
Phase 1 • Sponsor: BeOne Medicines • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Fish or puppets: which distraction works best for needle-phobic kids?
Symptom relief Recruiting nowThis trial tests whether two simple distractions — watching a betta fish or playing with a hand puppet — can lower pain, fear, and anxiety in children aged 5 to 7 during a blood draw. One group will use the fish, another the puppet, and a third will receive standard care. Researc…
Phase 1 • Sponsor: Igdir University • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New ointment put to the test against eczema
Symptom relief Recruiting nowResearchers are testing an experimental ointment called IN-115314 in adults with mild to moderate atopic dermatitis, a common form of eczema. The trial compares two strengths of the ointment, 1% and 3%, against a placebo ointment. Participants apply the treatment twice daily for …
Phase 2 • Sponsor: HK inno.N Corporation • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New trial tests filler for 'Ozempic Face'
Symptom relief Recruiting nowThis study tests whether Radiesse (calcium hydroxylapatite) injections can restore facial volume and improve skin quality in people who lose facial fullness from GLP-1 weight loss drugs like semaglutide. 48 adults starting GLP-1 therapy will be randomly assigned to receive either…
Phase 4 • Sponsor: Kalpna Kay Durairaj, MD, FACS • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a clotting drug in numbing shots cut bruising after nasal surgery?
Symptom relief Recruiting nowResearchers are testing whether adding tranexamic acid to standard numbing injections reduces bleeding, swelling, and bruising during and after nasal reconstruction surgery for skin cancer. The trial enrolls about 100 adults who are having a local flap repair of a nasal defect af…
Phase 2 • Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New drug aims to calm stubborn hives triggered by cold or scratching
Symptom relief Recruiting nowThis early-stage study tests a single dose of an experimental drug called GTX-B001 in healthy people and those with chronic inducible urticaria—a condition where cold or scratching causes painful hives. The main goal is to check safety and how the body handles the drug. About 72 …
Phase 1 • Sponsor: Granular Therapeutics Limited • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a serum plus a red light cap regrow hair?
Symptom relief Recruiting nowResearchers are testing whether a scalp-stimulating serum and a red light therapy cap, used alone or together, improve hair growth in women with female pattern hair loss. Forty women aged 35 to 55 apply the serum daily and wear the light cap at home for six months. The study meas…
Sponsor: K. Kay Durairaj, MD, FACS, A Medical Corporation • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a meditation app soothe teen eczema?
Symptom relief Recruiting nowThis trial tests whether regular use of a digital mindfulness meditation app can help adolescents aged 12-17 with moderate to severe atopic dermatitis (eczema) improve disease control and quality of life. Participants will use the app for 10-15 minutes, 3-4 times a week, while a …
Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Can a cream beat rosacea redness? new study tests it against placebo
Symptom relief Recruiting nowThis study tests whether a special dermocosmetic cream can reduce facial redness and visible blood vessels in people with a common type of rosacea. Fifty adults will apply the cream to one side of their face and a placebo to the other, twice daily for two months, then continue wh…
Sponsor: ISISPHARMA • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New eczema ointment shows promise in early trial
Symptom relief Recruiting nowThis Phase 2 study tests an experimental ointment called GX-03 in adults with moderate-to-severe eczema. About 110 to 200 participants will apply either the active ointment or a placebo for 8 weeks. Researchers will measure improvements in skin rash, itch, and patient-reported sy…
Phase 2/3 • Sponsor: Turn Therapeutics • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New pill could ease severe eczema itch and rash
Symptom relief Recruiting nowThis study tests an experimental daily tablet (PF-08049820) for adults with moderate to severe eczema (atopic dermatitis). About 165 participants will take either the study drug or a placebo for 12 weeks. Researchers will check skin improvement, itching, and safety through clinic…
Phase 2 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Can a simple ointment make surgical scars heal better?
Symptom relief Recruiting nowThis trial tests whether zinc oxide ointment improves scar healing compared with plain petrolatum after skin surgery. Adults with a surgical cut at least 4.5 cm long on non-scalp skin will apply each ointment to half of the scar daily for a month. Researchers will compare scar ap…
Early phase 1 • Sponsor: Melissa Pugliano-Mauro • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New radiation method may boost immune attack on tumors
Symptom relief Recruiting nowThis study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can a simple cream soothe psoriasis? new trial tests Urea-Based lotions
Symptom relief Recruiting nowThis study tests two medical creams containing urea (20% and 40%) on people with mild plaque psoriasis or non-pustular palmoplantar psoriasis. Each participant applies the cream to one affected area and leaves a similar area untreated for comparison. The goal is to see if the cre…
Sponsor: ICIM International S.r.l. • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Eczema drug dupilumab may lift anxiety and depression
Symptom relief Recruiting nowThis study tracks 184 people with moderate-to-severe atopic dermatitis (eczema) who are already starting dupilumab treatment. Over six months, researchers will measure changes in anxiety, depression, and quality of life using standard questionnaires. The goal is to see if treatin…
Sponsor: Sanofi • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Can a urea cream beat vaseline for nail psoriasis?
Symptom relief Recruiting nowThis study tests a cream called PROXERA PSOMED 30, which contains 30% urea, for treating nail psoriasis. 21 adults with nail psoriasis will apply the cream to one nail and Vaseline to another nail twice daily for 24 weeks. Researchers will compare how much each nail improves usin…
Sponsor: ICIM International S.r.l. • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Can sunscreen do more than protect? study tests if it fades dark spots
Symptom relief Recruiting nowThis study tests whether two types of facial sunscreen (untinted and tinted) can improve dark spots caused by melasma, sun spots, or post-inflammatory hyperpigmentation. Adult participants with mild to moderate dark spots apply the sunscreen at least twice daily for 56 days. Rese…
Sponsor: Kenvue Brands LLC • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Exercise after breast reconstruction: a new path to faster recovery?
Symptom relief Recruiting nowThis study looks at whether a structured 12-week exercise program can improve fitness and recovery in women who have had DIEP flap breast reconstruction after mastectomy. Half of the 78 participants will follow the exercise program, while the other half will receive standard care…
Sponsor: Royal College of Surgeons, Ireland • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Virtual workouts may protect heart health in breast cancer patients on chemo
Symptom relief Recruiting nowThis study tests whether a virtual exercise and education program can help breast cancer patients maintain their fitness, heart health, and quality of life while undergoing chemotherapy. About 120 patients with stage I-III breast cancer will be enrolled. Participants will attend …
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple injection tighten loose skin after major weight loss?
Symptom relief Recruiting nowThis study tests whether injections of Poly-L-lactic acid (PLLA) can improve skin laxity in people who have loose skin after bariatric surgery. Fifteen participants receive three injections in one thigh over three months, while the other thigh is left untreated. During later plas…
Sponsor: Nordberg Medical Italy srl • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can facial exercises ease the stiffness of scleroderma?
Symptom relief Recruiting nowThis study tests whether a personalized facial rehabilitation program can help people with systemic sclerosis who have facial tightness and mouth problems. About 60 adults with this rare autoimmune disease will either receive the rehab program or standard care. The goal is to see…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Mindfulness may soothe psoriasis stress
Symptom relief Recruiting nowThis study tests whether Mindfulness-Based Cognitive Therapy (MBCT) can reduce psychological distress and improve self-compassion in people with psoriasis. Researchers will enroll 128 adults with psoriasis who are experiencing emotional difficulties. Participants will either rece…
Sponsor: Islamia University of Bahawalpur • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Light therapy may soothe radiation burns in breast cancer patients
Symptom relief Recruiting nowThis study tests whether a special light therapy can reduce skin damage caused by radiation treatment in women with breast cancer. 60 women who have had breast-conserving surgery and are scheduled for radiation will either receive standard skin care alone or standard care plus po…
Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Cold plasma could heal stubborn wounds faster
Symptom relief Recruiting nowThis study tests whether a cold helium plasma device is safe and tolerable for people with chronic wounds, such as leg ulcers or pressure sores. About 40 adults with wounds that have not healed for over 4 weeks will receive the treatment. The goal is to see if cold plasma can red…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New hope for bedsores: physical therapy techniques tested in spinal cord injury patients
Symptom relief Recruiting nowThis study looks at whether two physical therapy techniques—pulsed wound irrigation and electrical stimulation—can help heal pressure injuries (bedsores) in people with spinal cord injuries. Forty adults in rehab will receive one of three treatments: both techniques, irrigation a…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Single-Incision armpit mastectomy could transform breast cancer surgery
Symptom relief Recruiting nowThis study is testing a new surgical technique for breast cancer called endoscopic nipple-sparing mastectomy, done through just one small cut in the armpit. The goal is to remove breast tissue while sparing the nipple and avoiding a large scar on the breast. Ten women with early-…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
New gel could soothe painful rash from cancer treatment
Symptom relief Recruiting nowThis study tests a topical gel called HT-001 for treating skin rashes, dryness, and nail problems caused by EGFR inhibitor cancer drugs. About 152 adults on these cancer therapies will apply the gel daily for 6 weeks. The goal is to see if it reduces rash severity and improves qu…
Phase 2 • Sponsor: Hoth Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
New injection aims to regrow hair in patchy baldness
Symptom relief Recruiting nowThis early-stage study tests whether ALD-102, a solution injected into the scalp, is safe and can help regrow hair in people with alopecia areata. About 24 adults aged 18-55 will receive either the drug, a placebo (saline), or no treatment in different scalp areas. The main goal …
Phase 1/2 • Sponsor: Aldena Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Could your environment trigger this rare muscle disease?
Knowledge-focused Recruiting nowThis study investigates whether certain environmental exposures—like infections, stress, or sun exposure—are more common in people with anti-synthetase syndrome, a rare autoimmune condition that causes muscle weakness and lung disease. Researchers will compare 580 participants, i…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Sep 21, 2026 20:00 UTC
-
Could childhood trauma fuel skin inflammation?
Knowledge-focused Recruiting nowThis study investigates how inflammatory genes are regulated in people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Researchers will compare inflammatory markers in HS patients versus healthy controls. An optional sub-study explores whether …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Sep 21, 2026 20:00 UTC
-
New study checks drug levels in breast milk for nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab passes into breast milk. Researchers will collect milk samples from 20 breastfeeding mothers with conditions like psoriasis or arthritis over several weeks. The goal is to understand potential exposure for nursing infants, not …
Phase 1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists dig into DNA of moles to uncover hidden mutations
Knowledge-focused Recruiting nowThis study collects moles and blood samples from 50 adults to analyze the genetic mutations that cause moles to form. Researchers will compare DNA from mole tissue with normal DNA from blood to find specific changes. No treatments or interventions are given—the goal is purely to …
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Smart camera foot scanner could replace pressure mats
Knowledge-focused Recruiting nowThis study will test a new device that uses a camera and machine learning to measure foot pressure and foot area. Researchers will compare it to the current standard pressure mat in 150 healthy adults. The goal is to see if the new tool is accurate and reliable enough for future …
Sponsor: Palacky University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists launch major study to unravel salivary gland mysteries
Knowledge-focused Recruiting nowThis study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists dig into skin healing mysteries in immune disorders
Knowledge-focused Recruiting nowThis study aims to understand how the immune system and skin healing are connected in people with primary immunodeficiency, psoriasis, or eczema, as well as in healthy volunteers. Researchers will collect skin biopsies, blood samples, and optional skin swabs to analyze microbes a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists dig into skin bugs to unlock eczema secrets
Knowledge-focused Recruiting nowThis study looks at the tiny organisms living on our skin—like bacteria and fungi—and how they might differ in people with eczema (atopic dermatitis). Researchers will collect skin samples from healthy volunteers and patients aged 2 to 40 with moderate to severe eczema, as well a…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists seek skin samples to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists probe how eczema drugs alter skin microbes
Knowledge-focused Recruiting nowThis study examines how common eczema treatments, including antibiotics and bleach baths, change the types and amounts of bacteria on the skin. Researchers will compare people with eczema to healthy volunteers. The goal is to understand the skin microbiome better, not to test a n…
Phase 2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Researchers launch major study to unravel mysteries of muscle disease
Knowledge-focused Recruiting nowThis study aims to learn more about myositis, a group of diseases that cause muscle inflammation and damage. Researchers will observe up to 1,200 children and adults with myositis, along with healthy volunteers, to track changes in the immune system and other health problems over…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive study aims to unlock secrets of food allergies
Knowledge-focused Recruiting nowThis study looks at the causes and effects of food allergies and related conditions like eczema and eosinophilic esophagitis. Researchers will collect blood, skin, and genetic samples from up to 1,800 people over many years. The goal is to find biomarkers and pathways that explai…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches major study to unlock secrets of rare bone diseases
Knowledge-focused Recruiting nowThis study aims to collect information and bone samples from up to 1,000 people with bone or mineral disorders, such as tumor-induced osteomalacia or familial tumoral calcinosis. Participants receive standard medical evaluations and may provide bone tissue from surgery or a biops…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for gene behind rare kidney cancer syndrome
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of hereditary leiomyomatosis renal cell cancer (HLRCC), a condition that can lead to painful skin bumps, uterine fibroids, and kidney tumors. Researchers will study people with known or suspected HLRCC and their family members to iden…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive study aims to uncover cancer secrets in rare bone marrow diseases
Knowledge-focused Recruiting nowThis natural history study follows up to 4,000 people with inherited bone marrow failure syndromes (IBMFS) and their families to learn why they are prone to certain cancers. Researchers will track health over time, collect genetic samples, and look for clues that separate those w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists seek samples to build better Cancer-Killing drugs
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Which technique best finds hidden breast tumors? large study puts localization methods to the test
Knowledge-focused Recruiting nowSurgeons use imaging-guided techniques to locate breast tumors they cannot feel, aiming to remove the cancer completely while sparing healthy tissue. This large observational study compares several methods, including wire-guided localization, intraoperative ultrasound, magnetic s…
Sponsor: European Breast Cancer Research Association of Surgical Trialists • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can chemotherapy tame a rare blood cancer? a look back at Real-World outcomes
Knowledge-focused Recruiting nowThis study looks back at the medical records of about 140 people with a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN) who received chemotherapy as their first treatment. The goal is to see how effective and safe different chemotherapy regimens are …
Sponsor: Stemline Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Eczema flare predictor device tested in new study
Knowledge-focused Recruiting nowThis study is testing a handheld device called Nevisense Go to see if it can predict eczema (atopic dermatitis) flares before they become visible or cause symptoms. About 450 people aged 12 to 89 with a history of eczema flares will use the device at home for 90 days. The goal is…
Sponsor: Castle Biosciences Incorporated • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Hormone tests may reveal who benefits most from acne drug
Knowledge-focused Recruiting nowResearchers at Biruni University are studying whether baseline blood levels of three hormones (DHEAS, FSH, and LH) are linked to how well adult women with moderate to severe acne respond to the drug isotretinoin. The trial enrolls 64 women aged 18 and older who are starting syste…
Sponsor: Biruni University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Wound dressings that trap microbes: scientists test a Drug-Free approach
Knowledge-focused Recruiting nowResearchers are investigating whether wound dressings coated with dialkylcarbamoyl chloride (DACC) can bind bacteria and fungi from hard-to-heal wounds. The study enrolls 30 adults with wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, or arterial leg ulcer…
Sponsor: ABIGO Medical AB • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Scleroderma's hidden link: could pelvic floor trouble track with weaker lungs?
Knowledge-focused Recruiting nowScleroderma often scars the lungs, which can weaken breathing muscles and make exercise harder. Researchers want to know whether pelvic floor problems, such as incontinence or pelvic pain, go hand in hand with these lung and breathing changes. The study enrolls 67 women with scle…
Sponsor: Biruni University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Rash or remission? new study aims to decode drug side effect in rare skin cancers
Knowledge-focused Recruiting nowThis study tracks 100 adults with mycosis fungoides or Sézary syndrome who are starting mogamulizumab, a standard treatment. The drug often causes a rash that can look like the cancer itself. Researchers want to help doctors tell the difference so they don't stop a working drug t…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New study tracks psoriasis Drug's Real-World impact on diverse skin types
Knowledge-focused Recruiting nowThis study follows 80 adults in Canada with moderate-to-severe psoriasis who are starting the drug tildrakizumab. Researchers want to see how the treatment affects quality of life and skin clearing over one year, especially in people with darker skin tones (Fitzpatrick type III a…
Sponsor: Chronicle Academy • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Fractal cues may restore natural gait in ACL rehab
Knowledge-focused Recruiting nowThis study compares two types of visual cues during treadmill walking in 36 athletes who had ACL reconstruction. One cue is a steady beat (isochronous), the other has natural fluctuations (fractal). The goal is to see which better restores natural walking patterns and brain activ…
Sponsor: Egas Moniz - Cooperativa de Ensino Superior, CRL • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
A glow of hope: UV imaging may reveal how well hair loss treatment will work
Knowledge-focused Recruiting nowThis study asks whether a red glow seen under ultraviolet light on the scalp can predict how well hair regrows in people with a type of hair loss called limited plaque alopecia areata. Adults who are already scheduled to receive corticosteroid injections as part of their regular …
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Hunting the hidden genes that decide who gets porphyria attacks
Knowledge-focused Recruiting nowAcute intermittent porphyria (AIP) is an inherited disorder that can cause sudden, severe attacks, but not everyone who carries the gene gets sick. Researchers at Mount Sinai are collecting blood, saliva, and urine samples from about 150 people in AIP families, including affected…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Could your genes raise your melanoma risk? new study seeks answers
Knowledge-focused Recruiting nowThis study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide b…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists launch global effort to unravel mysteries of rare lymphatic diseases
Knowledge-focused Recruiting nowThis study is creating a registry of up to 1,000 people with rare lymphatic system disorders. Researchers will collect information from medical records and yearly surveys to understand how these diseases progress, what treatments are used, and how they affect quality of life. The…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Scientists launch deep dive into rare bleeding and lung disease
Knowledge-focused Recruiting nowThis study aims to learn more about Hermansky-Pudlak Syndrome (HPS), a rare inherited disease that causes light skin/eye color, bleeding problems, and often deadly lung scarring. Researchers will follow 600 people with HPS and their family members to track how the disease progres…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
New marker could make breast cancer radiation more precise
Knowledge-focused Recruiting nowThis study tests a new way to mark the area where a breast tumor was removed, so radiation therapy can be more accurately aimed afterward. About 50 adults with early-stage breast cancer or a precancerous condition called DCIS will take part. The goal is to see if this marking hel…
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Could cutting salt soothe your skin? new study investigates
Knowledge-focused Recruiting nowThis study looks at whether changing how much salt you eat can affect skin sodium levels and the severity of eczema or psoriasis. Fifty adults will follow a low-salt diet and take either sodium tablets or a placebo for several weeks. The goal is to see if this approach is practic…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Can an eczema drug reshape the Skin's microbial community?
Knowledge-focused Recruiting nowResearchers are tracking how lebrikizumab, a treatment for atopic dermatitis, changes the community of fungi, bacteria, and Staphylococcus on the skin. The study enrolls 60 adults with eczema who are starting lebrikizumab. Skin swabs taken before treatment and at weeks 4 and 16 w…
Sponsor: University Hospital Bispebjerg and Frederiksberg • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
New patient registry aims to unlock secrets of rare liver disease
Knowledge-focused Recruiting nowThis study is a global registry that will follow about 150 people with acute hepatic porphyria (AHP) over time. Researchers will collect information on how the disease progresses, how it is managed in real-world settings, and the safety and effectiveness of approved treatments li…
Sponsor: Alnylam Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can imaging replace the scalpel for skin cancer checks?
Knowledge-focused Recruiting nowThis study tests three non-invasive imaging devices on adults with basal cell carcinoma, the most common skin cancer. Researchers measure how long each scan takes, how comfortable it feels, and how well the tools work on different body areas. Participants attend one 40-minute vis…
Sponsor: Bispebjerg Hospital • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
New tool aims to help breast cancer patients choose reconstruction
Knowledge-focused Recruiting nowThis study tests a decision aid called BREASTChoice in 20 breast cancer patients who had breast surgery. Participants use the tool on their phones and share their thoughts in interviews. Researchers measure how much patients learn about reconstruction options using a knowledge su…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Scientists investigate rare breast cancer subtype to improve future care
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 people with a rare type of breast cancer called apocrine lobular carcinoma. Researchers want to understand how this cancer behaves, what treatments patients received, and how they did over time. No new treatments are tested — the go…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Breast cancer drugs linked to blood sugar changes? new study investigates
Knowledge-focused Recruiting nowThis study is looking at how hormone treatments for breast cancer, called aromatase inhibitors and tamoxifen, affect blood sugar control and diabetes risk in postmenopausal women. Researchers will compare blood sugar measures in women taking these drugs to healthy women not on tr…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Gene-Guided surgery may spare kids from unnecessary knife
Knowledge-focused Recruiting nowThis study looks at whether using genetic markers from a child's skin tumor can help doctors decide how much surgery is needed. About 51 children and young adults up to age 25 with localized melanoma or similar growths will have their tumor tissue reviewed centrally. Based on ris…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
New registry hopes to unlock secrets of rare breast cancer
Knowledge-focused Recruiting nowThis study is creating a registry for people with a rare type of breast cancer called invasive lobular carcinoma that has spread. Researchers will collect data from about 12 participants to develop a new tool that better measures how well treatments are working. The goal is to im…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Scientists dig into immune signals to unlock psoriasis mystery
Knowledge-focused Recruiting nowThis study looks at 40 adults with psoriasis—some with joint pain (psoriatic arthritis) and some without—to compare immune signals in their blood and skin. Researchers want to understand why some people develop joint problems. Participants give blood and skin samples for lab anal…
Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Major study launches to unravel risks of birthmarks
Knowledge-focused Recruiting nowThis study follows 819 children under 2 years old who have medium to giant congenital nevi (pigmented birthmarks). Researchers will track neurological development, melanoma risk, and quality of life over time. The goal is to create better monitoring and treatment guidelines for t…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
New registry aims to unlock secrets of rare genetic condition in kids
Knowledge-focused Recruiting nowThis study is creating a registry for children with PTEN Hamartoma Tumor Syndrome (PHTS), a rare genetic condition that increases cancer risk. Researchers will follow 100 participants for 3 years to link genetic changes with health outcomes. The goal is to develop better monitori…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious immune condition
Knowledge-focused Recruiting nowThis study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
New registry tracks Real-World safety of FOP drug palovarotene
Knowledge-focused Recruiting nowThis registry study follows about 100 people with FOP, a rare disease where soft tissue turns to bone. Some participants take palovarotene (an approved treatment), while others do not. Researchers will track side effects, flare-ups, and daily function over time to see how well th…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Scientists study leishmania infections to improve diagnosis and care
Knowledge-focused Recruiting nowThis study looks at how leishmaniasis infections progress and respond to treatment. It involves up to 289 people aged 3 to 100 with known or suspected leishmaniasis. Researchers will collect blood and tissue samples to learn more about the disease and test different treatments. T…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can blood and skin markers predict lymphoma outcomes?
Knowledge-focused Recruiting nowThis study looks at blood and skin samples from people with mycosis fungoides and Sézary syndrome, rare types of lymphoma that affect the skin. Researchers want to find biological markers that can predict how the disease will progress and how well a patient might respond to treat…
Sponsor: Lund University Hospital • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can a national biobank network end the diagnostic odyssey for rare diseases?
Knowledge-focused Recruiting nowThis study aims to create a network of biobanks across Italy that collect and store biological samples and health data from people with rare diseases and their families. The goal is to standardize how samples are collected and shared, so researchers can access high-quality materi…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can leishmania antigens trigger a protective immune response?
Knowledge-focused Recruiting nowThis study investigates whether six specific Leishmania antigens can activate T-cells in blood and tissue samples from patients with visceral and cutaneous leishmaniasis. Researchers will compare responses before and after treatment, and against healthy volunteers, to see if thes…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Massive study aims to crack the code on Kids' medications
Knowledge-focused Recruiting nowThis study is collecting blood and other samples from 5,000 children and young adults (under 21) who are already taking certain medications as part of their regular care. The goal is to understand how these drugs move through and affect children's bodies, so doctors can prescribe…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Could gum bacteria fuel scleroderma? a new study digs in
Knowledge-focused Recruiting nowThis study investigates whether systemic sclerosis, a rare autoimmune disease, changes the community of bacteria living in the mouth. Researchers will collect dental plaque samples from 30 participants—some with scleroderma and some without—to compare the types and functions of o…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
AI aims to end Skin-Tone bias in dermatology
Knowledge-focused Recruiting nowThis study is testing whether artificial intelligence can accurately classify skin pigment, sun sensitivity (phototype), and sun damage from standard photos of the arm. Researchers will enroll 1,500 adults from diverse backgrounds, combining objective color measurements, expert a…
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can skin biopsies unlock new treatments for scleroderma?
Knowledge-focused Recruiting nowThis study aims to understand the cellular and molecular mechanisms behind systemic sclerosis (SSc), a rare autoimmune disease that causes skin and organ fibrosis. Researchers will collect skin punch biopsies and blood samples from 500 participants, including those with SSc and h…
Sponsor: Relation Therapeutics • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can mapping tumor DNA unlock personalized breast cancer care?
Knowledge-focused Recruiting nowThe AURORA study is collecting tumor and blood samples from 1,300 people with metastatic breast cancer across Europe. By analyzing genetic changes in both the original and metastatic tumors, researchers hope to understand why some patients respond well to therapy while others do …
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Rare disease mystery: can tracking SPLIS patients unlock its secrets?
Knowledge-focused Recruiting nowThis study follows people with SPLIS, a rare inherited metabolic condition, to map its natural history—how the disease unfolds over time. Researchers will track growth, organ function, quality of life, and survival in about 28 participants. The goal is to understand the full rang…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New gadget aims to take the guesswork out of measuring skin hardening in scleroderma
Knowledge-focused Recruiting nowThis study is testing a new device called ADHELASKIN to see if it can measure skin stiffness more accurately than the current method (feeling the skin by hand) in people with systemic sclerosis (scleroderma). The study will compare 100 participants: those with scleroderma and hea…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can ultrasound reveal why lipedema makes walking hard?
Knowledge-focused Recruiting nowThis study investigates how lipedema — a condition causing abnormal fat buildup in the legs — affects muscle structure and walking. Researchers will use ultrasound to measure leg muscle and tendon thickness in 45 women with lipedema and compare them to 45 healthy women. A foot-pr…
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can a new questionnaire better measure lipedema symptoms in turkish women?
Knowledge-focused Recruiting nowLipedema is a chronic condition causing painful fat buildup in the legs, mostly in women. This study is testing whether a Turkish translation of the Rapprich Lipedema Symptomatic Assessment Questionnaire is a reliable and valid tool for measuring symptom severity. Researchers wil…
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
Knowledge-focused Recruiting nowThis study compares oxygen readings taken from the finger and the earlobe during a six-minute walk test in people with interstitial lung disease. The goal is to see if one location gives more accurate measurements of oxygen levels during exercise. The results could help doctors d…
Sponsor: Hospital de Granollers • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Can a genetic hunt solve the mystery of a painful skin condition?
Knowledge-focused Recruiting nowLichen sclerosus is a chronic skin condition that causes itching, pain, and scarring, often in the genital area, and raises the risk of skin cancer. This study aims to identify genetic variants linked to the disease by analyzing DNA from families that have multiple members with l…
Sponsor: Gudula Kirtschig • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Italian study tracks Real-World use of secukinumab for painful skin condition
Knowledge-focused Recruiting nowThis study follows 250 Italian adults with moderate to severe hidradenitis suppurativa (a chronic skin disease causing painful lumps) who are starting secukinumab. Researchers will track how well the drug reduces skin lesions over time and how it affects healthcare use and costs.…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Skin sodium levels may hold clues to eczema in older adults
Knowledge-focused Recruiting nowThis observational study investigates factors linked to sodium stored in the skin of healthy adults and people with atopic dermatitis (eczema) aged 50 and older. Researchers aim to see if diet and skin barrier function affect skin sodium levels, and whether those levels are tied …
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Hidden heart risk: routine cancer scans could reveal cardiovascular danger in breast cancer survivors
Knowledge-focused Recruiting nowThis study tests whether measuring calcium buildup in heart arteries from routine radiotherapy planning CT scans can identify breast cancer patients at risk for heart disease. Researchers will share this personalized risk information with patients and their doctors to see if it i…
Sponsor: UMC Utrecht • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Scientists probe keloid tissue for clues to stop overgrown scars
Knowledge-focused Recruiting nowThis study looks at keloid scars—raised, overgrown scars that can be itchy or painful—to understand why they form. Researchers will compare keloid tissue with normal skin from the same person, using lab tests to spot key molecules that drive scar growth. The goal is to uncover ne…
Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Could starting immunotherapy earlier improve outcomes for High-Risk melanoma?
Knowledge-focused Recruiting nowThis study observes patients with high-risk stage II melanoma to see if starting anti-PD-1 immunotherapy before surgery leads to better outcomes compared to the usual timing after surgery. Researchers will track when patients begin systemic therapy and compare results between the…
Sponsor: AC Camargo Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
Knowledge-focused Recruiting nowThis study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
500-Person biobank aims to unlock secrets of autoimmune diseases
Knowledge-focused Recruiting nowThis study is creating a large collection of medical data and blood samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will use advanced lab techniques to find unique biological markers that could …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
AI reads skin lesions to predict cancer aggressiveness
Knowledge-focused Recruiting nowThis study tests whether an artificial intelligence (AI) model can accurately classify basal cell carcinoma (a common skin cancer) as low-risk or high-risk using dermoscopic images. Researchers will also see if the AI can predict specific subtypes of the cancer. The model's perfo…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
COVID-19's skin secrets: could chilblains hold clues to the virus?
Knowledge-focused Recruiting nowThis study looks at skin problems that appear during a COVID-19 infection, with a special focus on chilblains (painful red or purple bumps on fingers or toes). Researchers want to understand why these skin changes happen—whether from the virus itself, tiny blood clots, or inflamm…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study aims to unlock secrets of systemic sclerosis through patient samples
Knowledge-focused Recruiting nowThis study is gathering blood, stool, and skin samples from 100 adults with systemic sclerosis to learn more about the disease. Researchers will also track health information like skin thickness, lung function, and quality of life over time. The goal is to build a biobank for fut…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Worldwide eczema study aims to uncover disparities in care
Knowledge-focused Recruiting nowThis international study observes how people with atopic dermatitis (eczema) access healthcare, what treatments they receive, and how the disease affects their daily lives. Researchers will collect data from routine medical records of about 9,600 participants across multiple coun…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Worldwide study aims to uncover hidden patterns in hidradenitis suppurativa care
Knowledge-focused Recruiting nowThis international study observes how people with hidradenitis suppurativa (a chronic skin condition) access healthcare, what treatments they receive, and how the disease affects their quality of life. Researchers collect data from routine medical records across multiple countrie…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Heat-Sensing camera could spot wound infections before they worsen
Knowledge-focused Recruiting nowThis study looks at whether a harmless thermal camera can help doctors see how surgical wounds are healing after skin surgery. About 120 adults having skin lesions removed will have their wounds photographed with the camera. The goal is to catch problems like infection or slow he…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to make allergy testing safer for cancer patients on biologics
Knowledge-focused Recruiting nowThis study is testing how to safely perform skin allergy tests in people receiving biotherapies for cancers and blood disorders. Researchers will find the highest concentration of each biotherapy that does not cause a skin reaction in 9 out of 10 patients. The goal is to establis…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a skin biopsy tell your doctor which treatment will work?
Knowledge-focused Recruiting nowThis study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
World's largest psoriasis care study launches to uncover treatment gaps
Knowledge-focused Recruiting nowThis study observes how people with psoriasis receive care in different countries. Researchers will collect data from routine doctor visits to understand treatment patterns, disease severity, and quality of life. The goal is to identify gaps in healthcare delivery and improve out…
Sponsor: Julia Tatjana Maul • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
Knowledge-focused Recruiting nowThis study aims to learn why myotonic dystrophy type 1 affects children differently than adults, and why symptoms vary even within the same family. Researchers will observe 100 children (ages 0-17) through video calls and simple at-home activities, and analyze their genes from a …
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
5,000 patients to help unlock secrets of inflammatory heart disease
Knowledge-focused Recruiting nowThis study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Scientists dig into why diabetic wounds stay open
Knowledge-focused Recruiting nowThis study looks at why wounds heal slowly or not at all in people with diabetes. Researchers will collect blood and wound fluid from 250 adults with chronic wounds to compare immune cells between diabetic and non-diabetic participants. The goal is to understand the biological re…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
French study tracks Real-World skin cancer care for 1500 patients
Knowledge-focused Recruiting nowThis study follows 1,500 French patients with advanced cutaneous squamous cell carcinoma (a type of skin cancer) who need systemic treatment (medication that works throughout the body). Researchers will collect information from medical records and ongoing visits to see how treatm…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New database aims to crack the code on three rare skin cancers
Knowledge-focused Recruiting nowThis study is building a large French database of patients with three rare skin cancers: Merkel cell carcinoma, advanced basal cell carcinoma, and cutaneous adnexal carcinomas. Researchers will track up to 9,000 participants to learn how these cancers behave, what factors affect …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
AI reads your symptom stories to find hidden medical clues
Knowledge-focused Recruiting nowThis study collects anonymous symptom descriptions from 1,000 adults through an online platform. An AI tool then searches medical literature to see if it can find reliable biological signals in the free-text descriptions. The goal is to test how accurate and consistent the AI's f…
Sponsor: OpenGenome • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Female athlete study: hormones may change strength and hydration
Knowledge-focused Recruiting nowThis study looks at how natural menstrual cycles and birth control pills affect strength, hydration, and energy balance in 40 female athletes. Researchers will measure muscle strength, body water, and energy use at different times of the month. The goal is to better understand ho…
Sponsor: Faculdade de Motricidade Humana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
300 patients tracked to uncover hidden cancer risks in common mouth condition
Knowledge-focused Recruiting nowThis study follows 300 people with oral lichen planus (a chronic mouth condition) for at least 6 months to see how often it turns into oral cancer. Researchers will also look for patterns and risk factors that might predict this change. No new treatments are tested—the goal is si…
Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New study aims to unlock mysteries of rare sun allergy disorders
Knowledge-focused Recruiting nowThis observational study is gathering information on how erythropoietic protoporphyria (EPP) and X-linked porphyria (XLP) affect people aged 12 and older. Over 6 months, researchers will track symptoms, light exposure, and blood levels of protoporphyrin IX (PPIX) in 50 participan…
Sponsor: Portal Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
100,000 volunteers needed to unlock secrets of chronic diseases
Knowledge-focused Recruiting nowThis study is collecting health information, lifestyle data, and biological samples from up to 100,000 adults to help researchers better understand diseases like lupus, celiac disease, and kidney disease. Participants provide data and samples through a direct-to-patient platform.…
Sponsor: Joined Bio • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive biobank launches to unlock secrets of chronic inflammation
Knowledge-focused Recruiting nowThis study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Researchers track Real-World treatment of serious ENT infections
Knowledge-focused Recruiting nowThis study is observing how doctors manage complicated infections of the ears, nose, throat, and neck in both children and adults. Researchers will track standard treatments like surgery or medication to understand current practices. No new treatments are being tested; the goal i…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Scientists hunt for eye disease clues in your tears
Knowledge-focused Recruiting nowThis study collects tear samples from 300 people with dry eye, infectious keratoconjunctivitis, mucous membrane pemphigoid, or allergic conjunctivitis. Researchers will analyze the proteins and metabolites in tears to create a unique fingerprint for each condition. The goal is to…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Massive HS study aims to unlock secrets of debilitating skin disease
Knowledge-focused Recruiting nowThis study is creating a large registry of 3,000 people with hidradenitis suppurativa (HS), a painful and poorly understood skin condition. Researchers will collect medical information and biological samples over time to learn more about how HS progresses and what causes it. The …
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Patients and doctors join forces to redesign breast cancer care
Knowledge-focused Recruiting nowThis study aims to understand the current state of breast cancer care by surveying both patients and doctors. The goal is to identify gaps in communication and time management, and to develop new, patient-focused care models. About 2000 adults with breast cancer and their physici…
Sponsor: University Hospital Augsburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Blood and AI join forces to catch lung scarring early in rheumatic disease patients
Knowledge-focused Recruiting nowThis study aims to find better ways to detect lung scarring (interstitial lung disease) early in people with connective tissue diseases like scleroderma or rheumatoid arthritis. Researchers will analyze tiny particles in the blood called extracellular vesicles and use AI to exami…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for genes behind rare skin condition
Knowledge-focused Recruiting nowThis study aims to find the genes and genetic changes that cause aplasia cutis congenita (ACC), a rare condition where babies are born with missing patches of skin. Researchers will analyze DNA from 600 people with ACC and their family members. The goal is to better understand th…
Sponsor: UConn Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New french study aims to unlock secrets of severe acne
Knowledge-focused Recruiting nowThis study is creating a group of 200 acne patients at Nantes University Hospital to learn more about the disease. Researchers will track factors like acne severity, quality of life, and treatment costs, and collect skin samples. The goal is to better understand what makes acne w…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Rare genetic condition may disrupt fat tissue, raising diabetes risk
Knowledge-focused Recruiting nowThis study looks at whether people with vascular Ehlers-Danlos syndrome (vEDS), a rare genetic disorder that weakens blood vessels, also have problems with how their body stores and uses fat. Researchers will compare 12-17 adults with vEDS to similar adults without the condition …
Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Oxygen therapy under scrutiny: could it harm cancer Survivors' DNA?
Knowledge-focused Recruiting nowThis study looks at whether repeated sessions of hyperbaric oxygen therapy (HBOT) can damage DNA in people who have had radiation for cancer. HBOT is used to help heal tissues damaged by radiation, but it also creates reactive oxygen molecules that might harm DNA. Researchers wil…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Can science predict who will get sick in a heatwave?
Knowledge-focused Recruiting nowThis study looks at why some people get sick from heat and sun exposure while others don't. Researchers will monitor 80 healthy volunteers in Denmark and Greece as they undergo controlled heat and UV radiation in a lab. The goal is to develop personalized alerts and advice to hel…
Sponsor: University of Thessaly • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Massive new registry aims to unlock secrets of swallowing disorders
Knowledge-focused Recruiting nowThis study is creating a large database of information from 10,000 people with esophagus problems like GERD, achalasia, and other motility disorders. Researchers will collect data from standard tests to better understand these conditions. The goal is to improve diagnosis and trea…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
New study aims to speed up leishmaniasis diagnosis in kids
Knowledge-focused Recruiting nowThis study tracks 200 children in Italy with leishmaniasis, a parasitic infection that can affect the skin or internal organs. Researchers will look at how quickly the disease is diagnosed and treated, and how that affects recovery, relapse, and death rates. The goal is to identi…
Sponsor: Meyer Children's Hospital IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Researchers track blistering skin disease to pave way for better treatments
Knowledge-focused Recruiting nowThis study looks at how severe autoimmune blistering diseases like pemphigus and bullous pemphigoid are and how they affect quality of life. Researchers will enroll 150 adults to test disease severity scales and quality-of-life questionnaires. The goal is to create better tools f…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Can exercise change how aging athletes feel pain?
Knowledge-focused Recruiting nowThis study looks at how former athletes, current master's athletes, and nonathletes (ages 35-65) experience pain and respond to moderate exercise. Participants will do strength and aerobic exercises while their pain tolerance and sensitivity are measured. The goal is to understan…
Sponsor: Marquette University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New database study aims to better understand dermatomyositis skin symptoms
Knowledge-focused Recruiting nowThis study collects information from people with dermatomyositis to better understand how the disease affects their skin and quality of life. Researchers will use a special scoring tool called CDASI to measure skin changes over time. The goal is to improve knowledge about the dis…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
5G Radiation's hidden impact on skin revealed in new trial
Knowledge-focused Recruiting nowThis study looks at how high-frequency 5G waves (27.5 GHz) affect the skin. Researchers will expose healthy volunteers and people with certain skin conditions to these waves and analyze skin cell changes using advanced techniques. The goal is to understand any biological effects,…
Sponsor: Prof. Olivier Gaide, MD-PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists launch hunt for clues in autoimmune skin diseases
Knowledge-focused Recruiting nowThis study aims to create a large collection of blood samples and medical information from 800 people with autoimmune or inflammatory skin diseases. Researchers will use these samples to find new biomarkers and better understand what causes these conditions. The goal is to help d…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New study investigates whether social struggles fuel inflammation in breast cancer patients
Knowledge-focused Recruiting nowThis pilot study looks at how social determinants of health—like housing, food, and transportation—relate to inflammation in women newly diagnosed with breast cancer. Participants fill out surveys and give a blood sample at a single visit. The goal is to understand these connecti…
Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Blood samples could unlock secrets of autoimmune diseases
Knowledge-focused Recruiting nowThis study aims to collect blood samples and medical data from 3000 people with autoimmune diseases like lupus, scleroderma, and myositis. Researchers will use these samples to find new biomarkers and better understand these conditions. The goal is to help develop new treatments …
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC